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73 ABSTRACT
Chromosome bands 11q22-q23 have been found frequently deleted in a number of
solid tumors and lymphoproliferative disorders, suggesting the existence of tumor
suppressor gene(s) in this area. This abnormality has been found in mantle cell
lymphoma (MCL) and chronic lymphocytic leukemia (CLL) by comparative genomic
hybridization studies (Karhu et al., 1997; Monni et al., 1998). By using the samples
from MCL and CLL patients, we wanted to identify the minimal common region of
deletion in 11q22-q23 and the candidate gene in the region. We also wanted to study
the occurrence of the deletion in 11q22-q23 in different types of lymphoma. Because
MCL is a relatively newly identified disease entity whose molecular background is
not well known, it was also our aim to study the gene expression profiles of MCL and
its blastoid variant.
Altogether we studied samples from 158 lymphoma or leukemia patients. One
hundred and fifty-two samples were studied using fluorescence in situ hybridization
(FISH) with YAC (yeast artificial chromosome) probes from 11q22.1-q23.3. Two
critical regions were identified in 11q22-q23, one represented by YAC755b11 and the
other by YAC785e12. The presence of the deletion in 11q23 is frequent in MCL, and
the abnormality is present in a small fraction of CLL/SLL (small lymphocytic
lymphoma) and diffuse large B-cell lymphoma cases. Our results showed the possible
correlation of the deletion in 11q23 with the development of leukemia from localized
lymphoma, and with the development of the Richter’s syndrome. One candidate gene
in 11q23, the PPP2R1B gene, was examined. The mutation analysis of this gene has
suggested that the pathogenic role of the PPP2R1B gene in MCL and CLL is
probably minor and it is not likely to be the target of the deletion in 11q23. In study
V, we used the cDNA array technology to study the gene expression profiles of
common and blastoid variant MCL. We studied 18 samples from MCL patients and
identified marker genes for both common and blastoid variant MCL. We also created
a disease subtype (common vs blastoid variant) classifier, which might be helpful in
the differential diagnosis of MCL.
Some of the results obtained from this thesis work have already been utilized
in the diagnosis of lymphomas.
84 INTRODUCTION
Non-Hodgkin’s lymphoma (NHL) is a heterogeneous group of neoplasms of the
immune system with distinct morphological, immunohistochemical, genetic and
clinical features. To correctly classify and diagnose different subgroups of NHL is
essential in order to treat the patients successfully.
One of the important criteria for lymphoma classification and diagnosis is the
genetic abnormality associated with different lymphoma subgroups. It is widely
acknowledged that cancer is a genetic disease, resulting from the accumulation of
gene mutations. At the microscopic level, it is manifested by the structural
abnormalities of the chromosomes. Research conducted over the past 30 years has
shown that clonal chromosomal abnormalities in tumor cells are distributed non-
randomly throughout the genome. Different neoplasms have distinctive chromosomal
abnormality profiles involving different chromosomes, chromosomal arms, bands and
sub-band regions. On the other hand, many abnormalities are associated with certain
diseases or disease subgroups only (Heim & Mitelman, 1995).
In this thesis, we studied abnormalities of one particular chromosome part,
namely the deletion in chromosome bands 11q22-q23, in several types of NHL, in
particular mantle cell lymphoma and chronic lymphocytic leukemia. Our intention
was to determine the molecular background of this abnormality and to investigate any
clinical correlation it might have. We further studied mantle cell lymphoma on the
gene expression level in order to understand more about the pathogenesis of this
disease.
Modern genetic research is characterized by the technical advancement.
Various novel techniques and methods enable research on both the single-gene and
the genome level. Results obtained in recent years have greatly improved our
knowledge of the diseases. Today, the use of many of the techniques, such as the
chromosome banding analysis and the fluorescence in situ hybridization analysis, is
considered an important part in disease diagnosis and prognosis.
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5.1 Lymphocytic malignancies
5.1.1 Classification of lymphoma
Non-Hodgkin’s Lymphoma (NHL) is a heterogeneous group of neoplasms of the
immune system. The classification of NHL is not a simple task, because many
different cell types are involved. Moreover, the neoplasms can originate in virtually
any organ, and patients with some types of lymphoma can develop leukemia. It is of
great importance to correctly classify and diagnose the different subgroups of NHL in
order to treat these diseases successfully. A common system of classification helps
clinicians and pathologists all over the world to communicate and exchange
information. Since 1925, at least 25 classification systems have been developed for
NHL. The ones that can be regarded as milestones are the Rappaport classification
(Rappaport, 1966), the Kiel classification (Lennert, 1978; Stansfeld et al., 1988), the
Lukes and Collins classification (Lukes & Collins, 1974), the Work Formulation for
Clinical Usage (Non-Hodgkin's Lymphoma Pathologic Classification Project, 1982),
the Revised European-American Lymphoma (REAL) classification (Harris et al.,
1994) and the WHO (World Health Organization) classification (Jaffe et al., 2001).
The history of NHL classification clearly reflects our increasing understanding of the
nature of different subgroups of NHL. The focus of the classification criteria has
gradually shifted from pure morphology or clinical behavior to include neoplastic cell
morphology, immunophenotype, genetic background, normal cell counterpart and
clinical features. In other words, all the current information is now used collectively
to define the disease entities. The development of NHL classification also reflects the
amazing technical and instrumental advances in the field over the past 40 years. New
technologies allow more thorough study of the diseases, leading to a more profound
understanding of them [for review see (Isaacson, 2000)].
The classification systems most widely in use now are the REAL classification
and its updated version - the WHO classification (Table 1), which were both jointly
drawn up by experts from Europe and the United States. In both classification
systems, lymphomas are classified based on five properties: morphology,
immunophenotype, genotype, normal cell counterpart and clinical features. In
addition to malignancies originated from B and T cells, Hodgkin’s lymphoma and
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malignancies originated from natural killer (NK) cells are also included. The REAL
classification has been proved to be highly practical and reproducible (Lymphoma
Classification Project, 1997). Many specific genetic abnormalities were associated
with particular lymphoma subtypes identified by the REAL/WHO classification (Jaffe
et al., 2001), proving the accuracy of the classification at the molecular level. The
experience gained from developing the REAL and WHO classification could also be
used in the classification of other types of cancer and will be important for the future
development of lymphoma classification (Harris et al., 2000).
It is clear from the history of NHL classification that there has been an
evolution in the process. With the development of new technologies and the
acquisition of new data, new disease entities may be identified, and uncertainties will
be clarified. This is already taking place. For example, new subtypes of diffuse large
B-cell lymphoma (DLBCL) have been identified using the microarray technology
(Alizadeh et al., 2000) and new subtypes of chronic lymphocytic leukemia (CLL)
have been recognized by analyses of the Ig V gene mutation and the expression of
CD38 (Damle et al., 1999; Hamblin et al., 1999). There is also more and more
information being gathered on the correlation between genetic markers and patients’
clinical behavior. It is possible that, in the future new approaches based on genetics
and molecular biology may play an important role in NHL classification.
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Table 1. The World Health Organization classification of lymphoid malignancies
(Jaffe et al., 2001)
B-cell neoplasms
Precursor B lymphoblastic leukemia/lymphoma
Chronic lymphocytic leukemia/small lymphocytic lymphoma
B-cell prolymphocytic leukemia
Lymphoplasmacytic lymphoma
Splenic marginal zone lymphoma
Hairy cell leukemia
Plasma cell myeloma
Monoclonal gammopathy of undetermined significance
Solitary plasmacytoma of bone
Extraosseous plasmacytoma
Primary amyloidosis
Heavy chain diseases
Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid
tissue (MALT-lymphoma)
Nodal marginal zone B-cell lymphoma
Follicular lymphoma
Mantle cell lymphoma
Diffuse large B-cell lymphoma
Mediastinal (thymic) large B-cell lymphoma
Intravascular large B-cell lymphoma
Primary effusion lymphoma
Burkitt lymphoma/leukemia
T-cell and NK-cell neoplasms
Precursor T lymphoblastic leukemia/lymphoma
T-cell prolymphocytic leukemia
T-cell large granular lymphocytic leukemia
Aggressive NK cell leukemia
Adult T-cell leukemia/lymphoma
 Mycosis fungoides
Sézary syndrome
Primary cutaneous anaplastic large cell lymphoma
Lymphomatoid papulosis
Extranodal NK/T cell lymphoma, nasal type
Enteropathy-type T-cell lymphoma
Subcutaneous panniculitis-like T-cell lymphoma
Angioimmunoblastic T-cell lymphoma
Peripheral T-cell lymphoma, unspecified
Anaplastic large cell lymphoma
Blastic NK cell lymphoma
Hodgkin lymphoma
Nodular lymphocyte predominant Hodgkin lymphoma
Classical Hodgkin lymphoma
Nodular sclerosis classical Hodgkin lymphoma
Mixed cellularity classical Hodgkin lymphoma
Lymphocyte-rich classical Hodgkin lymphoma
Lymphocyte-depleted classical Hodgkin lymphoma
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5.1.2 Mantle cell lymphoma
Mantle cell lymphoma (MCL) is a malignant non-Hodgkin’s lymphoma of B cell
lineage. The normal cell counterpart of the malignant cell of MCL is the immature
CD5+ virgin B cell in the mantle zone of lymphoid follicles (Harris et al., 1994).
MCL has been described variously since its initial recognition in the mid-1970s, such
as lymphocytic lymphoma of intermediate differentiation (Berard & Dorfman, 1974),
centrocytic lymphoma (Lennert & Feller, 1990) and mantle zone lymphoma
(Weisenburger et al., 1981). It was later shown (Banks et al., 1992) that these
lymphomas were in fact one disease entity and given the name mantle cell lymphoma.
MCL accounts for 2.5% to 4.0% of all NHL cases in the United States, and 7% to 9%
in Europe (Weisenburger & Armitage, 1996). MCL patients are characterized by
advanced age, male predominance, presentation at advanced stages, and frequent
involvement of bone marrow, peripheral blood and other external sites (Fisher et al.,
1995; Norton et al., 1995; Teodorovic et al., 1995; Velders et al., 1996; Argatoff et
al., 1997). The median survival of MCL patients is only 3 to 4 years in most large-
scale series, even after combination chemotherapies for aggressive lymphomas
(Oinonen et al., 1998), so that MCL is regarded as an incurable disease.
The common form of MCL is characterized by small to medium-sized
lymphocytes with scant cytoplasm. The nuclei usually have slightly irregular-contours
with dispersed chromatin and inconspicuous nucleoli (Harris et al., 1994). As in
chronic lymphocytic leukemia (CLL), CD5 and pan B-cell antigens (CD19, CD20,
CD22, and CD24) are usually co-expressed on MCL neoplastic cells. The feature
distinguishing MCL cells from CLL cells is the expression of CD23, which is positive
for CLL and usually negative for MCL. CD20 and immunoglobulin light chain
expression is usually strong in MCL and weak in CLL, which is also a useful
distinction. However, exceptions have been identified in both diseases. In addition to
the common form of MCL, a so-called large cell or blastoid variant of the disease has
been identified (Jaffe et al., 1987; Fisher et al., 1995; Ott et al., 1997). Greiner et al.
described three subtypes of the variant form of MCL: blastic; anaplastic; and
centrocytoid-centroblastic (Greiner et al., 1996), whereas Ott et al. identified only two
types of variant (lymphoblastoid and pleomorphic variant) based on morphology (Ott
et al., 1997). Regardless of the morphological sub-classification, the feature
distinguishing blastoid variant MCL from the common MCL is the high mitotic rate
13
(Jaffe et al., 1987; Ott et al., 1994; Fisher et al., 1995). Around 30% of MCL patients
develop the more aggressive blastoid variants that progress more rapidly and shorten
survival (Norton et al., 1995; Greiner et al., 1996).
5.1.3 Chronic lymphocytic leukemia
Historically, chronic lymphocytic leukemia (CLL) has two subtypes: B-cell chronic
lymphocytic leukemia (B-CLL) and T-cell chronic lymphocytic leukemia (T-CLL).
About 97% of CLL cases are B-CLL (Bennett et al., 1989). In the WHO lymphoma
classification, however, CLL is recognized as a B-cell neoplasm only. The disease
previously known as T-CLL is now recognized as T-cell prolymphocytic leukemia or
large granular lymphocyte leukemia (Jaffe et al., 2001). Here we will use the term
CLL as defined by the WHO lymphoma classification. Small lymphocytic lymphoma
(SLL) cases have the same tissue morphology and immunophenotype as CLL cases.
CLL involves primarily bone marrow and peripheral blood, while SLL is usually non-
leukemic, although exceptions exist in both diseases. Therefore, CLL and SLL are
considered one disease entity (Harris et al., 1994; Jaffe et al., 2001).
CLL is the most common leukemia in adults in western countries and accounts
for one fourth of all leukemia cases (Rozman & Monserrat, 1995). CLL affects mostly
elderly patients, only 10% to 15% of patients are younger than 50 years at the time of
diagnosis. There is a gender bias so that the disease affects more men than women
(ratio approximately 2:1). Although the cause of the disease is not completely
understood, one suggestion is the failure of malignant cells to undergo apoptosis. It
has been shown that CLL patients accumulate mature monoclonal CD5+ lymphocytes
and that these cells are arrested in the G0/G1 phase of the cell cycle (Bannerji & Byrd,
2000).
The immunophenotype of typical CLL malignant cells are: weak IgM or IgM
and IgD, CD5+, CD19+, weak CD20, weak CD22, CD79a+, CD23+, CD43+, weak
CD11c, CD10-, cyclin D1-, and FMC7 and CD79b negative or weakly expressed.
Matutes et al. (1994) developed a scoring system for differential diagnosis of CLL
from other types of B-cell leukemia based on the immunophenotype. Typical CLL
case has a score of five, which means CD22-, CD23+, CD5+, FMC7- and
undetectable or weak Igκ/λ (Matutes et al., 1994).
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The normal cell counterpart of the leukemia cells in CLL was originally
thought to be the virgin B cell. However, recent studies have shown that the normal
cell counterpart is the virgin B cell in only about 50% of cases of CLL, and that it is
the memory B cell in the other cases (Damle et al., 1999; Hamblin et al., 1999). The
same studies have shown that the disease is less malignant in those cases where the
normal cell counterpart is the memory B cell, than when the normal cell counterpart is
the virgin B cell.
CLL is usually considered an incurable disease with currently available
therapies. The clinical course of CLL is in general indolent, but varies a lot among
patients. Some patients can live asymptomatically for many years, while others die
within five years after diagnosis. There are two staging systems – Rai and Binet – in
use for predicting the survival. The Rai staging system defines five stages (0-IV) with
increasingly worse prognosis: lymphocytosis alone (stage 0); lymphocytosis,
lymphadenopathy (stage I); lymphocytosis, spleen or liver enlargement or both (stage
II); lymphocytosis, anemia with hemoglobin less than 11.0 g/dl (stage III);
lymphocytosis, thrombocytopenia with platelet count less than 100,000 /mm3 (stage
IV) (Rai et al., 1975). The Binet staging system defines three stages (A-C) with
increasingly worse prognosis: no anemia, no thrombocytopenia, less than three areas
enlarged (A); no anemia, no thrombocytopenia, three or more areas enlarged (B);
anemia with hemoglobin less than 10.0 g/dl, or thrombocytopenia with platelet count
less than 100,000/mm3, or both (C) (Binet et al., 1981).
Around 3.5% of CLL cases transform to high-grade lymphoma, a process
referred to as Richter’s syndrome (Richter, 1929; Foucar, 1992). Around 3% of the
Richter’s syndrome cases transform to diffuse large B-cell lymphoma, and the rest
transform to lymphomas resembling Hodgkin’s lymphoma.
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5.2 11q and genetic aberrations in non-Hodgkin’s lymphoma
5.2.1 Genes and abnormalities in 11q
Chromosome 11 represents about 4.8% of the relative autosome length, is estimated
to be 144 Mb in size, and has 997 genes assigned to it. The long arm of chromosome
11, 11q, is estimated at around 90 Mb and has 673 genes assigned to it
(http://www.ncbi.nlm.nih.gov). Genes are non-uniformly distributed along 11q,
clustering mostly in three regions, 11q13, 11q22-q23 and 11q24. Proto-oncogenes
EMS1, FGF3 (INT2), FGF4 (HST), CCND1 (PRAD1), BCL1 and GSTP1 are located
in 11q13. The candidate gene for MEN1 (multiple endocrine neoplasia type 1) has
been localized to 11q13.1 (Chandrasekharappa et al., 1997), as has PGL2, one of the
two paraganglioma (PGL) candidate genes located on chromosome 11q (Mariman et
al., 1993). The translocation t(11;22)(q24;q12), present in about 90% of cases of
Ewing’s sarcoma and neuroepithelioma (Turc et al., 1984), involves the oncogene
FLI1 in 11q24 (Hromas et al., 1993). The gene encoding the protein kinase CHK1, a
checkpoint protein for the G2 to M phase transition, is located in 11q24 (Sanchez et
al., 1997). In 11q24 there is also the ETS1 gene, which is homologous to the viral ets
oncogene of the E26 virus, and acts as a transcription factor in regulating cell
proliferation, differentiation, lymphoid cell development, angiogenesis and apoptosis
(Li et al., 1999).
Chromosome bands 11q22-q23 are frequently involved in translocations and
deletions in a variety of neoplasms. Figure 1 shows the schematic integrated physical
map of this region (Arai et al., 1996). The most common chromosomal translocations
in this region are those involving the MLL gene, of which more than 40 different ones
have been described and 19 partner genes have been cloned (Osaka et al., 1999;
Schreiner et al., 1999). These translocations are present in about 5% of patients with
acute myeloid leukemia, and up to 10% of patients with acute lymphocytic leukemia
(Kaneko et al., 1986). In addition, they are seen in up to 80% of cases of infant acute
myeloid leukemia and acute lymphocytic leukemia (Heerema et al., 1994). Around
85% of patients with topoisomerase II inhibitor-related secondary leukemia have
these translocations (Pedersen-Bjergaard & Rowley, 1994).
Cytogenetic and loss of heterozygosity (LOH) analyses have shown that
chromosome bands 11q22-q23 are frequently deleted in a number of solid tumors
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(breast, cervical, ovarian, gastric, lung, bladder, prostate, nasopharyngeal, squamous
and colorectal carcinomas; malignant melanomas and intracerebral neoplasms)
(Foulkes et al., 1993; Keldysh et al., 1993; Carter et al., 1994; Hampton et al., 1994a;
Hampton et al., 1994b; Bethwaite et al., 1995; Gabra et al., 1995; Herbst et al., 1995;
Iizuka et al., 1995; Koreth et al., 1995; Negrini et al., 1995; Rasio et al., 1995; Shaw
& Knowles, 1995; Winqvist et al., 1995; Baffa et al., 1996; Blaeker et al., 1996;
Davis et al., 1996; Gabra et al., 1996; Hui et al., 1996; Tomlinson & Bodmer, 1996;
Uzawa et al., 1996; Dahiya et al., 1997; Koreth et al., 1997), as well as in
lymphoproliferative disorders (Heim & Mitelman, 1995). These results strongly
suggest the presence of tumor suppressor gene(s) in this region. Functional evidence
for the existence of tumor suppressor gene(s) in 11q has been provided by microcell
fusion experiments involving the transfer of normal chromosome 11 or part of it into
malignant melanoma, breast, lung, cervical and ovarian cancer cell lines. Transfer of
the whole chromosome 11, the chromosome bands 11q13-q23 or their fragments
suppressed the in vitro growth of the cells (Gioeli et al., 1997), and the in vivo
tumorigenesis (Negrini et al., 1994; Zenklusen et al., 1995; Robertson et al., 1996;
Murakami et al., 1998) and metastatic potentials (Phillips et al., 1996) of the cells in
nude mice. While the length of the deleted regions varies between tumor types, two
minimum common regions of deletion (common to three or more tumor types) were
found in 11q22.3-q23.1 and 11q23.2-q23.3.
The minimal common region of deletion in 11q22.3-q23.1 has been found to
be 2-3 Mb in size, and contain the ATM  gene and a region represented by
YAC755b11 (Stilgenbauer et al., 1996; Koreth et al., 1999). Other studies showed
that the minimal critical region was only the region represented by YAC755b11 (1.6
Mb in size) (Monni et al., 1999; Zhu et al., 1999). ATM encodes a serine-threonine
kinase belonging to a protein family related to phosphoinositide kinases which
includes ATR, Mec1, Tel1 and Rad53 (Elledge, 1996). ATM detects DNA damages
and activates p53, Chk2 and Mdm2 to promote apoptosis or cell cycle arrest. ATM
also activates c-Abl in response to stress signals. In addition, ATM is required for
DNA repair and insufficient DNA repair will lead to genomic instability (Baskaran et
al., 1997; Shafman et al., 1997; Banin et al., 1998; Canman et al., 1998; Matsuoka et
al., 1998; Brown et al., 1999; Johnson et al., 1999). Inactivation of the ATM gene and
the corresponding loss of ATM protein function result in ataxia telangiectasia, a
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disorder characterized by atrophy of the cerebellum and thymus, immunodeficiency,
premature aging, predisposition to cancer, and sensitivity to ionizing radiation
(Savitsky et al., 1995). Mutations of the ATM gene have been found in CLL, MCL
and T-cell prolymphocytic leukemia cases (Stilgenbauer et al., 1997; Bullrich et al.,
1999; Schaffner et al., 1999; Stilgenbauer et al., 1999; Schaffner et al., 2000;
Camacho et al., 2002). The PPP2R1B gene is located very close to the region
represented by YAC755b11. PP2A is a regulatory enzyme that negatively regulates
the MAPK cascade and has been linked to carcinogenesis (Hunter, 1995). The
PPP2R1B gene has 15 exons and encodes the β isoform of the structural/regulatory A
subunit of the PP2A gene. It was found to be mutated in human lung and colon
cancers, and identified as a putative tumor suppressor gene (Wang et al., 1998). But
no mutation was found in hereditary PGL (Baysal et al., 1998), and rarely in ovarian
carcinomas (Campbell & Manolitsas, 1999; Wu et al., 1999), parathyroid hyperplasia
and adenomas (Hemmer et al., 2002), CLL or MCL (Zhu et al., 2001). Therefore, its
role as a tumor suppressor gene remains to be confirmed.
The 11q23.2-q23.3 region was found frequently deleted in cutaneous
malignant melanoma (Herbst et al., 1999), ovarian cancer (Launonen et al., 1998),
cervical carcinoma (Mugica-Van Herckenrode et al., 1999), lung cancer (Wang et al.,
1999), breast cancer (Launonen et al., 1999), CLL (Zhu et al., 1999) and MCL
(Monni et al., 1999). A tumor suppressor gene, TSLC1 (for tumor suppressor gene in
lung cancer-1), was recently identified in non-small-cell-lung cancer. This gene is
located in a 100 kb area in the center of the region represented by YAC939b12
(Murakami et al., 1998; Kuramochi et al., 2001). 11q23.2 is also the region where the
gene responsible for hereditary PGL is located. PGL is a rare disorder characterized
by the development of mostly benign, highly vascular, slow-growing tumors in the
head and neck. The succinate-ubiquinone oxidoreductase subunit D gene (SDHD) was
recently identified as the hypothesized gene PGL1. SDHD is a critical component of
the oxygen-sensing system of paragangliomic tissue. The loss of its function may lead
to chronic hypoxic stimulation and cellular proliferation (Baysal et al., 2000). It will
be interesting to examine the roles of these two genes in other types of neoplasms.
A retinoid-induced class II tumor suppressor / growth regulatory gene was
found to be involved in CLL and located in 11q23 (DiSepio et al., 1998). Its exact
location and role in other types of cancer deserve further investigation.
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5.2.2 Chromosomal abnormalities in non-Hodgkin’s lymphoma
Tumor cells exhibit clonal chromosomal abnormalities that are non-randomly
distributed throughout the genome. It has been shown that many types of cancer have
distinctive chromosomal aberration profiles, and some chromosome aberrations are
unique to certain types of cancer or cancer subgroups (Heim & Mitelman, 1995).
Many NHL subgroups have characteristic chromosomal translocations. For
example, t(14;18)(q32;q21) is found in 70% to 90% of follicular lymphoma cases,
resulting in deregulation of the oncogene BCL2 (Tsujimoto et al., 1985). MCL is
characterized by t(11;14)(q13;q32), which is found in 50% to 70% of cases and
involves the oncogene BCL1 (Weisenburger & Armitage, 1996). t(8;14)(q24;q32) is
found in 75% to 85% of Burkitt’s lymphoma and involves the CMYC gene (Dalla-
Favera et al., 1982). The translocation t(9;22)(q34;q11) creates an oncogenic fusion
gene BCR-ABL, and is found in 85% of cases of chronic myeloid leukemia and 15%-
20% of cases of acute lymphocytic leukemia (Heim & Mitelman, 1995).
Trisomies of chromosomes 3, 7, 12 and 18 have been found in NHL with
varying frequencies (Heim & Mitelman, 1995). Other chromosomal amplifications
detectable using cytogenetic analysis techniques, such as double minute chromosomes
and homogeneously staining regions, are rarely detected in NHL (Ben-Yehuda et al.,
1994). Comparative Genomic Hybridization (CGH) studies have revealed several
highly amplified regions in NHL, and oncogenes in these regions were also found to
be amplified [reviewed by (Knuutila et al., 1998)].
The most common chromosome deletion sites in NHL include 6q, 11q, 13q
and 14q (Heim & Mitelman, 1995). In addition, CGH studies have found frequent
chromosome deletions in 1p, 8p, 9p, 12p, 12q and 17p in NHL (Knuutila et al., 1999).
The characteristic chromosomal aberrations in NHL detected by chromosome banding
analysis are summarized in Table 2.
Recurrent observation of deletion in a chromosome in tumor samples by
cytogenetic analysis often indicates the existence of a putative tumor suppressor gene.
Tumor suppressor genes encode proteins that function in cell growth regulatory or
differentiation pathways, and loss of their function induces cells to develop malignant
phenotypes (Vogelstein & Kinzler, 1998). The loss of function of tumor suppressor
genes usually follows the “two-hit” model originally proposed to explain the
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development of retinoblastoma by Alfred Knudson (Knudson, 1971). According to
this model, two mutagenic events (hits) are required for the tumor suppressor genes to
stop functioning. In familial cancers, the first hit is present in the germline and the
second hit comes as a somatic mutation. In sporadic cancers, both mutagenic events
are somatic. Inactivation of a tumor suppressor gene often occurs through the deletion
of one allele and mutation of the other. In addition to cytogenetic analysis, tumor
suppressor genes can also be identified through DNA linkage analyses attempting to
locate genes involved in an inherited predisposition to cancer, and through LOH or
allelic loss studies (Vogelstein & Kinzler, 1998). Examples of known and putative
tumor suppressor genes have been summarized by Knuutila et al. (1999).
Table 2. Characteristic chromosomal aberrations in malignant lymphoma and
lymphocytic leukemia [a modification of (Heim & Mitelman, 1995)]
Rearrangement Gene(s) involved Types of lymphoma /
Leukemia
1p and 1q
rearrangements
? Variable B- or T-cell NHL,
Hodgkin lymphoma, multiple
myeloma, plasma cell leukemia
t(1;19)(q23;p13) E2A;PBX1 Acute lymphocytic leukemia
t(2;3)(p12;q27) IGK;LAZ3/BCL6 Diffuse large B-cell or
follicular lymphoma
t(2;5)(p23;q35) ALK;NPM Ki-1 lymphoma
t(2;8)(p12;q24) IGK;MYC Burkitt lymphoma, acute
lymphocytic leukemia
t(2;18)(p12;q21) IGK;FVT1 Follicular lymphoma
+3 ? Variable B- or T-cell NHL
3q rearrangements ? Variable B- or T-cell NHL,
Hodgkin lymphoma
t(3;14)(q27;q32) LAZ3/BCL6;IGH Diffuse large B-cell or
follicular lymphoma
t(3;22)(q27;q11) LAZ3/BCL6;IGL Diffuse large B-cell or
follicular lymphoma
6p rearrangements ? T-cell NHL
del(6q) ? Variable, mostly B-cell NHL,
Hodgkin lymphoma, acute
lymphocytic leukemia, chronic
lymphocytic leukemia, hairy
cell leukemia, T-cell
prolymphocytic leukemia
+7 ? Variable B- or T-cell NHL
7q rearrangements ? Hodgkin lymphoma
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t(8;14)(q24;q32) MYC;IGH Burkitt lymphoma, acute
lymphocytic leukemia
t(8;22)(q24;q11) MYC;IGL Burkitt lymphoma, acute
lymphocytic leukemia
9q rearrangements ? Variable B- or T-cell NHL
t(9;14)(p13;q32) PAX5;IGH Small lymphocytic lymphoma
t(9;22)(q34;q11) BCR;ABL Acute lymphocytic leukemia
t(10;14)(q24;q11) HOX11;TCRD T-cell acute lymphocytic
leukemia
t(10;14)(q24;q32) LYT10;IGH Variable B-cell NHL
del(11q) ? Chronic lymphocytic leukemia,
mantle cell lymphoma
t(11;14)(q13;q32) BCL1/PRAD1;IGH Mantle cell lymphoma, chronic
lymphocytic leukemia, multiple
myeloma, plasma cell leukemia
t(11;18)(q21;q21) ? Small lymphocytic lymphoma,
mucosa-associated lymphoid
tissue (MALT) lymphoma
rearrangement of 11q23 MLL; multiple fusion genes Acute lymphocytic leukemia
+12 ? Small lymphocytic or diffuse
large B-cell lymphoma, chronic
lymphocytic leukemia, B-cell
prolymphocytic leukemia
12p rearrangements ? Hodgkin lymphoma
13p rearrangements ? Hodgkin lymphoma
del/+(13q) ? Chronic lymphocytic leukemia
14q+ ? Chronic lymphocytic leukemia,
B-cell prolymphocytic
leukemia, hairy cell leukemia,
multiple myeloma, plasma cell
leukemia
14q11 rearrangements TCRA;TCRD T-cell NHL, T-cell
prolymphocytic leukemia
del(14q) ? Variable B- or T-cell NHL
14q32 rearrangements IGH Variable B-cell NHL, Hodgkin
lymphoma
t(14;18)(q32;q21) IGH;BCL2 Follicular or diffuse large B-
cell lymphoma
del(17p) ? Chronic lymphocytic leukemia
+18 ? Variable B- or T-cell NHL
t(18;22)(q21;q11) BCL2;IGL Follicular lymphoma
-X/+X/-Y ? Variable B- or T-cell NHL
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5.2.3 Genetic aberrations in mantle cell lymphoma
Over-expression of cyclin D1 is a characteristic feature of MCL. A recent study by
Yatabe et al. showed that 85% of MCL cases were cyclin D1 positive. They suggested
that the cyclin D1 positive and negative cases might actually represent different
disease entities, with the cyclin D1 positive cases representing typical MCL, while the
cyclin D1 negative cases could be better described as “cyclin D1-negative MCL-like
B-cell lymphoma” cases (Yatabe et al., 2000). The over-expression of cyclin D1 in
more than 70% of the cases are caused by the t(11;14) chromosomal translocation
(Williams et al., 1992).  MCL was also found to be characterized by the inactivation
of the ATM gene (Stilgenbauer et al., 1999; Schaffner et al., 2000; Camacho et al.,
2002). P53 mutations were found in some MCL cases, and it was suggested that these
mutations were correlated with a poor prognosis (Greiner et al., 1996). In the blastoid
variants of MCL, abnormalities of the cyclin-dependent kinase inhibitor genes
P16INK4a and P21Waf1, were also found (Pinyol et al., 1997; Pinyol et al., 1998).
CGH studies have shown that MCL cases have a rather different pattern of
chromosomal alterations compared to ones detected in other types of NHL. The most
common abnormalities were recurrent gains in 3q, 7p, 8q, 12q, 15q, 18q and 9q34,
and losses in 1p, 6q, 9p, 10p14-p15, 11q14-q23, 13 and 17p (Monni et al., 1998; Beà
et al., 1999). Blastoid variant MCL was found to have increased number of
chromosomal imbalances, high-level DNA amplifications, and a tendency to be
tetraploid (Ott et al., 1997; Beà et al., 1999).
5.2.4 Genetic aberrations in chronic lymphocytic leukemia
CLL has been reported in ataxia telangiectasia families (Swift et al., 1987), although
no evidence of linkage between CLL and the ATM gene was found (Bevan et al.,
1999). Somatic deletion or point mutation affecting both alleles of the ATM gene have
been reported (Schaffner et al., 1999). Germ line mutations of the ATM gene have
also been found in one third of CLL patients (Bullrich et al., 1999), and total or partial
inactivation of ATM protein in up to 40% of patients (Stankovic et al., 1999). Patients
with decreased expression of the ATM protein have more aggressive disease and
shorter survival (Starostik et al., 1998). In about 95% of cases of CLL there is
increased expression of the BCL2 oncogene, due to DNA hypomethylation in the
BCL2 promoter region (Hanada et al., 1993). Mutations of the P53 tumor suppressor
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gene were seen in 15% of patients and patients with P53 mutations had more
aggressive disease (Cordone et al., 1998). Some CLL patients have leukemic cells
showing high-level expression of P27Kip1, whose protein product normally decreases
as a cell progresses into S phase. Such patients may have shorter blood lymphocyte
doubling time and shorter survival than the average CLL patient (Vrhovac et al.,
1998).
Chromosome banding analysis reveals clonal chromosome aberrations in
around 40-50% of CLL patients (Juliusson & Gahrton, 1990; Juliusson et al., 1991).
This technique is likely to underestimate the prevalence of clonal chromosome
aberrations because the leukemic cells have low spontaneous mitotic activity and
respond poorly to mitogenic stimulation (Autio et al., 1987). When mitogenic
stimulation is optimized, clonal chromosome aberrations were found in up to 79% of
CLL patients (Larramendy et al., 1998). CGH and interphase fluorescence in situ
hybridization (FISH) techniques have also greatly facilitated the detection of
chromosomal aberrations in CLL.
The most frequent chromosomal aberrations were found to be deletions in 13q,
11q, 6q and 17p, and trisomy 12 (Döhner et al., 1999). The aberration in 13q mainly
involves the chromosome band 13q14, where the retinoblastoma tumor suppressor
gene (RB1) resides. It has been speculated that RB1 could have a pathogenic role in
CLL, but the results so far have been contradictory. The pathogenic gene is thought
more likely to be located distal to RB1 and efforts at positional cloning have been
made (Liu et al., 1997; Corcoran et al., 1998; Stilgenbauer et al., 1998). Patients with
the 11q deletion were shown to represent a subset of CLL characterized by extensive
nodal involvement and poor prognosis (Döhner et al., 1997). Recently, cDNA
microarray analysis has revealed a distinctive gene expression profile for CLL
patients with the 11q23 deletion (Aalto et al., 2001). Trisomy 12 was the most
frequent chromosomal aberration found using chromosome banding analysis, with the
frequency ranging from approximately 7% to more than 25% (Juliusson & Gahrton,
1990). Trisomy 12 was shown to be related to atypical morphology and poor
prognosis (Escidoer et al., 1993; Que et al., 1993; Criel et al., 1994; Matutes et al.,
1996). Patients with deletions in chromosome 17 usually have the poorest prognosis
and this aberration is the only one of independent prognostic value (Bentz et al.,
1999; Döhner et al., 2000).
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5.3 Recent technological advances in molecular cytogenetics
5.3.1 Chromosome banding analysis
The chromosome banding technique was first introduced in 1968 (Caspersson et al.,
1968), and has ever since played a central role in genetic research and clinical
applications (Heim & Mitelman, 1995). However, cytogenetic analysis is sometimes
very problematic due to the difficulties in obtaining high quality metaphase or
prometaphase spreads of dividing neoplastic cells, in order to fix and stain the
chromosomes properly before the microscopic examination, especially in solid
tumors. Consequently, chromosome banding analysis data for neoplasms are the most
abundant for leukemias (63%), followed by solid tumors (27%) and lymphomas
(10%) (Mitelman, 1994). In addition, chromosome structural rearrangement involving
segments smaller than a band (around 10 Mb) cannot be detected using the banding
analysis (Heim & Mitelman, 1995, page 24).
5.3.2 FISH
The FISH analysis utilizes the specific base pairing of two complementary nucleic
acid sequences, one from the probe and the other from the target that is fixed on a
microscopic slide. The interaction between the probe and the target can be visualized
under the microscope through direct or indirect fluorescence labeling of the probe.
The FISH technique is widely used in chromosome structure studies and for genome
mapping.
Probes
The probes used in FISH can be broadly assigned to two groups: the probes for
repetitive sequences and the locus-specific probes.
Examples of probes for repetitive sequences are the centromere specific
probes. Chromosome centromere specific probes have been developed for all human
chromosomes except chromosomes 13 and 21. Other locations that provide good
hybridization targets using probes for repetitive sequences are the distal end of
chromosome 1p (Buroker et al., 1987) and the long arm of the Y chromosome (Lau &
Schonberg, 1984).
Locus-specific probes identify unique sequences of individual genes or
genomic loci. These probes are available in vectors of plasmid, phage, cosmid (Feiss
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et al., 1982), P1 (Sternberg, 1990), PAC (P1 derived artificial chromosome) (Ioannou
et al., 1994), BAC (bacterial artificial chromosome) (Shizuya et al., 1992), or YAC
(yeast artificial chromosome) clones (Burke et al., 1987). These host vectors allow
inserts of different sizes to be conveniently incorporated, from a few kb of plasmid or
phage clones, to 35-40 kb of cosmid clones, to 80-100 kb of P1 clones, to 100-200 kb
of PAC clones, to 100-300 kb of BAC clones, and up to 300-2000 kb of YAC clones.
These large-sized locus-specific probes have greatly facilitated the physical mapping
of the genome. YAC contig maps covering the whole human genome have been
constructed. However, YAC probes are relatively unstable, having low cloning
efficiencies and a high degree of chimerism (Cohen et al., 1993). A transformation
associated recombination method that utilizes Alu and LINE repetitive elements of the
human genome has been used in the production of YAC probes to lower the level of
chimerism (Larionov et al., 1996). P1, PAC and BAC probes also provide more stable
alternatives to YAC probes. In addition to physical mapping, the locus-specific probes
have been widely used in molecular genetic studies (discussed below), as well as for
constructing bar code systems (Uhrig et al., 1999) and matrix-CGH systems (Solinas-
Toldo et al., 1997).
Targets 
The relaxation level of the target DNA affects the detection resolution. DNA is
mostly tightly packed at metaphase and can be resolved to 1-2 Mb (Pinkel, 1999).
Mechanically stretched chromosomes (MSCs) have a better resolution of
approximately 200 kb (Laan et al., 1995). However, the resolution of MSCs is not
uniform across different chromosomes and chromosome regions (Laan et al., 1995).
Different methods have been used to produce free DNA fibers on microscopic slides
as targets and they are termed as fiber-FISH techniques (Florijn et al., 1995). The
resolution using fiber-FISH is around 1 kb (Heiskanen et al., 1996).
Another important use of FISH is to obtain information from interphase nuclei
where metaphase spreads are difficult to obtain. Interphase FISH has a resolution
level of 50 kb-1 Mb (Trask et al., 1989).
Studies using FISH
Centromere specific probes are often used to detect the chromosome copy number in
interphase nuclei (Cremer et al., 1986) or in prenatal diagnosis where numerical
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aberrations are the most common abnormalities (Klinger et al., 1992). FISH technique
has been used to study the interphase chromosome topography (Emmerich et al.,
1989), the spatial relationship between different satellite regions within a
chromosome (Rocchi et al., 1991), different models of chromosome aberrations
(Lucas & Sachs, 1993), the DNA replication (Rosenberg et al., 1995), numerical
aberrations and translocations in metaphase and interphase nuclei (Tkachuk et al.,
1990; Losada et al., 1991; Ried et al., 1992), the non-disjunction in sperm (Williams
et al., 1993), and the aneusomy in sperm (Spriggs et al., 1995; Martin et al., 1996;
Spriggs et al., 1996). The FISH technique has also been applied to determine the
location of YAC and cosmid clones by using metaphase, prophase and interphase
chromosomes (Lichter et al., 1990; Inazawa et al., 1994; Windle et al., 1995). The
location and structure of many genes have been studied using FISH on MSCs and
DNA fibers (Vrolijk et al., 1996; Wang et al., 1996).
5.3.3 Other FISH-based techniques
CGH
To cope with the shortcomings of the banding analysis, the CGH technique was
invented in 1992 (Kallioniemi et al., 1992; du Manoir et al., 1993). CGH is used to
measure the relative abundance of tumor DNA along each chromosome. DNA copy
number changes of 10-20 Mb in size can be detected accurately using CGH
(Kallioniemi et al., 1994). Amplifications of smaller regions can be detected if they
are at least 1 Mb in size and are more than 5-10 fold amplified. Loss of a region 10-12
Mb in size is also detectable if the loss is present in a large portion of the cell
population (Bentz et al., 1998). CGH has been successfully utilized in both research
and diagnosis [reviewed in (Knuutila et al., 1998; Knuutila et al., 1999)].
The main advantage of the CGH technique is that one does not need to culture
the tumor cells. It helps to avoid the potential genetic alterations developed during
long-term culturing and the problems associated with the low metaphase yield of
malignant cells. CGH can also reveal the genetic composition of marker
chromosomes, homogeneous staining regions and double minutes. The disadvantage
of CGH is that balanced translocations, inversions, small deletions and polyploid
karyotypes are not detectable. In addition, a DNA copy number change has to be
present in at least 50% of the cells in the sample for it to be detected (Kallioniemi et
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al., 1994). This may cause problems in heterogeneous tumors and tumors with normal
cell infiltration.
Multicolor fluorescence in situ hybridization
To increase the sensitivity of the chromosome banding analysis, several multicolor
fluorescence in situ hybridization systems were developed in the mid-90s to identify
all 24 human chromosomes by different colors. The multiplex-fluorescence in situ
hybridization (M-FISH) system (Speicher et al., 1996), the spectral karyotyping
(SKY) system (Schröck et al., 1996) and the COmbined Binary RAtio (COBRA)
labeling system (Tanke et al., 1999) utilize different labeling and detection methods
to visualize each chromosome in its own color. The multicolor analysis has been
successfully applied to elucidate complex chromosome rearrangements (Veldman et
al., 1997). The resolution limit of these systems has not been well established. The
current consensus is that aberrations smaller than 2.6 Mb in size are difficult to be
detected (Haddad et al., 1998; Uhrig et al., 1999; Azofeifa et al., 2000).
In addition to whole chromosome paints, multicolor analysis using locus-
specific DNA probes can create artificially banded chromosomes (bar code)
(Lengauer et al., 1993; Chudoba et al., 1999). The bar code system is able to increase
the detection sensitivity and accuracy, yield information on mosaicism, and reveal
structural rearrangements undetectable by other methods. The combined use of
chromosome banding analysis, CGH, and multicolor fluorescence in situ
hybridization together with the bar code system will give us the maximum
cytogenetic information (Uhrig et al., 1999).
5.3.4 Array technology
The array technology is a variation of in situ hybridization where hundreds or
thousands of targets are attached to a small solid support. The solid support can be
either filter or glass (DNA chip). The technology was developed in the late 1990s to
make full use of the huge number of gene specific sequences identified by the Human
Genome Project, and the abundant information on disease-related gene mutations. In
the past few years,  the array technology has quickly evolved into a highly technical
field involving miniaturization, automation, multicolor fluorescent labeling, and
database driven sample and data management (Wilgenbus & Lichter, 1999).
28
Oligonucleotide array and cDNA array
In an oligonucleotide array, oligonucleotides are either synthesized directly on the
surface of the chip, or pre-synthesized and then deposited onto the chip. Several in
situ synthesis methods have been developed for this purpose and usually synthesize
oligonucleotides of less than 25 bases long [reviewed by (Watson et al., 1998)].  In
the printing method, pre-synthesized oligonucleotides are covalently attached to
chemically treated glasses (Chu et al., 1983; Guo et al., 1994; Joos et al., 1997). The
oligonucleotide array is suitable for comparing complementary targets with single
base mismatched sequences, such as in the analysis of mutations or single-nucleotide
polymorphisms and in mini-sequencing analysis. To study gene expression, multiple
oligonucleotides for one gene are needed.
The cDNA array technique is used to study the expression levels of a gene
population. cDNA clone inserts are amplified by polymerase chain reaction (PCR)
and attached to the solid support utilizing non-covalent charge interactions [reviewed
by (Watson et al., 1998)]. The non-covalent nature of the interaction between the
target and the solid support may result in the loss of the target clones during the
hybridization reaction, leading to reduced sensitivity and inconsistency. However,
because the cDNA array is relatively easy to prepare, it is widely in use nowadays.
A variety of applications have been developed using oligonucleotide array and
cDNA array, such as the detection of disease-relevant genes and mutations (Hacia et
a l . , 1996; Su et al., 2000), and the characterization of single-nucleotide
polymorphisms for linkage analysis (Cargill et al., 1999; Halushka et al., 1999). The
technology has also been widely used in gene expression profiling of different
physiological status (Ross et al., 2000), linking gene expression patterns to clinical
information and cytogenetic abnormalities (Martin et al., 2000; Virtaneva et al.,
2000), disease class discovery and prediction (Golub et al., 1999; Alizadeh et al.,
2000; Bittner et al., 2000; Kihara et al., 2001), and profiling of the pharmacological
and toxicological properties (Nuwaysir et al., 1999; Scherf et al., 2000).
Matrix-CGH
To overcome the limitation of the resolution in conventional CGH, the matrix-based
CGH was developed, where hundreds or even thousands of genomic DNA target
clones are immobilized on a solid support. The immobilized targets can be cosmid,
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P1, PAC, BAC or YAC clones. Matrix CGH has significantly better resolution than
conventional CGH. High copy number amplifications can be detected at a resolution
of 10 kb and the smallest detectable low copy number gains or losses are
approximately 100 kb in size (Solinas-Toldo et al., 1997; Wilgenbus & Lichter,
1999). One can also hybridize the genomic DNA directly onto cDNA arrays, which
increases sensitivity to a single gene level (Heiskanen et al., 2000). The matrix CGH
technique has been used in gene hunting projects (Albertson et al., 2000) and the
detection of disease-relevant genomic imbalances (Bruder et al., 2001).
Tissue array
Another new development in the array field is the tissue array technology. Kononen et
al. (1998) described a method to attach up to 1,000 tissue sections onto a slide. The
tissue array can be used to study genomic DNA deletions and amplifications
(Bubendorf et al., 1999), mRNA expression (Kononen et al., 1998) and tissue
immunohistochemistry (Sallinen et al., 2000). The tissue array technique is often used
in combination with the oligonucleotide or cDNA array technique. Genes identified in
the expression profiling analysis using the oligonucleotide or cDNA microarray
techniques can be verified on a tissue array composed of a large number of tumor
samples (Moch et al., 1999).
Data management
An essential pre-requisite for the optimal use of microarray data is the development of
sufficient tools for collecting, storing, retrieving and querying data, regardless of the
technology platform used to generate it (Ermolaeva et al., 1998). The Microarray
Gene Expression Database (MGED) group (http://www.mged.org) aims to promote
the adoption of standards in array experiments and data. The group has developed
recommendations for microarray data annotations. A number of different statistical
methods have been investigated for array data analysis. To date, hierarchical
clustering analysis has been the most commonly used algorithm applied to array
analysis data (Eisen et al., 1998). Other analysis algorithms that have been applied
include k-means clustering, Bayesian clustering (Golub et al., 1999), self-organizing
maps (Tamayo et al., 1999) and principal component analysis (Hilsenbeck et al.,
1999).
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6 AIMS OF THE STUDY
• To characterize the deletion in chromosome bands 11q22-q23
• narrowing down the minimal common region of deletion
• examining the occurrence of the deletion in different lymphoma subtypes
• testing of one candidate gene in the region
• To study the gene expression profiles of mantle cell lymphoma and its blastoid
variant
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7 MATERIAL AND METHODS
7.1 Patients
Altogether samples from 158 lymphoma or leukemia patients were included in this
thesis study. Thirty-six CLL samples came from patients attending the CLL out-
patient clinic at Tampere University Hospital, and the rest of the samples came from
Helsinki University Central Hospital. There were altogether 53 MCL samples, 68
CLL/SLL (small lymphocytic lymphoma) samples, 17 DLBCL (diffuse large B-cell
lymphoma) samples, 9 FL (follicular lymphoma) samples and 11 HL (Hodgkin
lymphoma) samples. Some of the MCL and CLL/SLL samples were used in more
than one study. The patient information is summarized in Table 3. One pathologist
classified all the lymphoma samples according to the REAL classification (Harris et
al., 1994). The diagnosis and staging of CLL were based on standard clinical,
morphological and immunophenotyping criteria (Rai et al., 1975; Binet et al., 1981;
Bennett et al., 1989; BCSH, 1994). The histology of the samples and methods used in
each study are summarized in Table 4.
Table 3. Patient information
Disease type No. cases Age (average) Sex (F/M)*
mantle cell lymphoma 53 45-90 (65) 20/33
chronic lymphocytic leukemia/
small lymphocytic lymphoma
68 38-84 (64) 20/48
diffuse large B-cell lymphoma 17 40-83 (65) 9/8
follicular lymphoma 9 41-75 (59) 6/3
Hodgkin lymphoma 11 10-76 (37) 7/4
*F, female; M, male.
In study I, paraffin embedded samples from 41 MCL patients were studied by
FISH analysis. The samples consisted of 34 primary lymphomas and eight recurrent
ones. In one case, both the primary tumor and a recurrent tumor were examined. The
samples were from 24 men and 17 women. The patient age at the time of the biopsy
ranged from 45 to 87 years (median, 63 years). Four patients had stage I lymphoma at
diagnosis, five stage II, one stage III, and 31 stage IV, according to the Ann Arbor
classification (Carbone et al., 1971). Seven of the lymphomas were regarded as
blastoid variants and two samples contained a mixture of blastoid morphology cells
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and typical morphology cells. Nuclei extracted from paraffin-embedded tissue of
reactive lymphatic tissues from two individuals were used as the control.
In study II, heparinized peripheral blood specimens were collected from 30
CLL patients and studied by FISH analysis. Twenty-two of the patients were men and
eight were women. The age of the patients ranged from 48 to 79 years (median, 64
years). The CLL-scores (Matutes et al., 1994) ranged from 3 to 5. Peripheral blood
from two healthy persons was used as the control.
In study III, FISH analysis was performed on 161 samples, comprising 47
MCL samples, 62 CLL/SLL samples, 17 DLBCL samples, 9 FL samples, 11 HL
samples and 15 reactive or normal lymph node samples (used as controls). Forty-one
MCL and 29 CLL/SLL samples were embedded in paraffin and all the others were
either peripheral blood or fresh tissue samples.
In study IV, 36 CLL samples and 37 MCL samples were included. Mutation
analysis of the PPP2R1B gene was carried out on these samples. DNA and RNA
extracted from the peripheral blood of two healthy individuals were used as controls.
In study V, samples from 18 MCL patients were investigated by cDNA array
analysis. The age of the patients at diagnosis ranged from 51 to 87 years (median, 65
years). There were 11 men and seven women. Fourteen of the patients (78%) were at
Ann Arbor stage III-IV (Carbone et al., 1971) at diagnosis. All the samples used in
this study were taken at diagnosis before any treatment. Nine lymphomas were
classified as common MCL and nine as the blastoid variant. Total RNA was extracted
from deep-frozen tumor tissue specimens. B-cells were purified from adenoid palatine
tonsil samples from six healthy children, using microbeads conjugated to monoclonal
CD 19 antibodies (Miltenyi Biotec, Bergisch Gladbach, Germany). The pooled total
RNA was extracted and used as the control.
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Table 4. Histology of the samples and the methods used in studies I – V.
Disease
type
Total
case no.
Immuno-
phenotypes
No. of positive
cases / no. of
cases studied
Methods
Study I MCL 41 CD5+
CD19+
CD20+
CD23-
IgM+
IgD+
κ+
λ+
cyclin D1+
38/40
27/27
39/39
28/28
31/31
29/32
12/33
21/33
39/41
FISH
Study II CLL 30 CD5+
CD22-
CD23+
FMC7-
undetectable or
weak lgκ/λ
26/29
28/29
28/29
29/29
16/29
G-banding
analysis,
FISH
Study III MCL 47 CD5+
CD20+
CD23-
cyclin D1+
44/46
45/45
30/30
43/47
G-banding
analysis,
FISH
CLL/SLL 62 CD5+
CD20+
CD23+
54/57
27/27
52/53
DLBCL 17 CD20+ 14/14
FL 9 CD20+
Bcl-2+
6/6
6/7
Classic
Hodgkin’s
lymphoma
7 CD30+
CD15+
CD3+
7/7
7/7
7/7
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Lymphocyte
predominant
Hodgkin’s
lymphoma
4 CD20+
CD15-
CD30-
CD3+
CD20+ (small
cells in nodules)
4/4
3/4
3/4
4/4
2/4
Study IV CLL 36 CD5+
CD22-
CD23+
FMC7-
undetectable or
weak Igκ/λ
31/35
34/35
34/35
35/35
19/35
RT-PCR,
Sequencing,
Single Strand
Conformation
Polymorphism
(SSCP),
MCL 37 CD5+
CD19+
CD20+
CD23-
IgM+
IgD+
κ+
λ+
cyclin D1+
34/36
27/27
35/35
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7.2 Immunohistochemistry (study I-V)
The immunohistochemistry was performed on paraffin and / or fresh sections using
either the biotin-avidin method or the streptavidin-biotin method. The work was done
by the pathologist’s laboratory at the time of diagnosis.
7.3 G-banding analysis (study II and III)
G-banding analysis of the samples in study II and III was performed at the time of
diagnosis in the Chromosome and Molecular Cytogenetic Laboratory at the Helsinki
University Central Hospital. The cells were detached mechanically from fresh lymph
biopsies in 5 ml RPMI 1640 medium (Gibco) supplemented with 20% calf fetal
serum, 1% glutamine, and 1% penicillin-streptomycin. The cell suspension was
treated with colcemid (0.1 µg/ml) in 5% CO2 at +37˚C for 4 to 12 hours. After
hypotonic treatment with 75 mM KCl, the cells were fixed three times in methanol-
acetic acid (3:1). Heparinized peripheral blood from leukemia patients was collected
and mononuclear cells were isolated and cultured with optimal mitogenic stimulation.
After harvesting, the cells were treated hypotonically (0.075 M KCl, 15 minutes,
+37˚C) and fixed with methanol-acetic acid (3:1). The cell suspension was spread on
slides and air-dried for a couple of days. G-banding analysis was performed according
to standard protocols. Images of the metaphase spreads were generated by IKAROS
programme (MetaSystems GmbH, Altlussheim, Germany) and ten metaphase spreads
of each sample were analyzed. Karyotypes were determined according to the
International System for Human Cytogenetic Nomenclature 1995 (Mitelman, 1995).
7.4 Interphase fluorescence in situ hybridization (studies I – III)
7.4.1 Sample preparation
Paraffin embedded samples We extracted the nuclei from paraffin embedded tissues
according to protocols described by others (Heiden et al., 1991; Hyytinen et al., 1994)
with slight modifications. The sections were deparaffinized with xylene 4 times at
+55°C and once at +67°C, which was followed by treatment in 100%, 95%, 70% and
50% ethanol series and in H2O at room temperature. After deparaffinization, sections
were digested in 1 ml of Carlsberg's solution (0.1% Sigma protease XXIV, 0.1 M
Tris, 0.07 M NaCl, pH 7.2) for 1 hour at +37°C and vigorously shaken in a vortex
machine for 20 minutes. The nuclear suspension was filtered through a nylon net
(pore size 55 µm) and spread on slides. The nuclei preparations were deparaffinized
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again just before the reaction, to ensure high quality hybridization, by incubating the
slides at +65°C for 15 minutes and washing them 3 times in xylene at room
temperature, followed by dehydration in 100%, 85%, 70% and 50% ethanol series.
Fresh tissue and peripheral blood samples Cells from fresh tumor tissues were
separated and cultured overnight in RPMI media [80%RPMI 1640, 20% fetal calf
serum, 0.29 mg/ml L-glutamine, 100 mg/ml streptomycin, 100 U/ml penicillin, 0,1
µg/ml Colcemid (all from Gibco, Grand Island, NY, USA)]. Heparinized peripheral
blood of leukemia patients was collected and mononuclear cells were isolated and
cultured with optimal mitogenic stimulation as described elsewhere (Larramendy et
al., 1998). After harvesting, cells were treated hypotonically (0.075 M KCl, 15
minutes, 37˚C) and fixed with methanol-acetic acid (3:1). The cell suspension was
then spreaded on slides.
7.4.2 Probes
In study I, 20 YAC probes covering the region 11q22.1-q23.3 contiguously (Figure 1.
on page 18) were obtained from the Centre d'Etude Polymorphisme d'Humain (CEPH,
Paris, France). All probes were screened with the corresponding markers using PCR
and FISH analysis to confirm their identities and locations. None of the probes
showed chimerism, as all hybridized only to 11q22-q23. YAC probes 808c6 and
953e4, hybridizing to 11p13, were used as controls of hybridization efficiency and for
evaluating the chromosome copy number. Seventeen MCL cases were tested with all
20 probes. Twenty-four MCL cases were screened with probe 755b11 first. Cases
found to have the 11q23 deletion were tested with a wider set of probes from the
YAC contig to determine the extent of the deletion. Probe 981g12, which represents
the region containing the ATM  gene, was tested on cases that did not show the
deletion of the region represented by YAC755b11 to eliminate the possibility that the
deletion in 11q23 was not uniformly detected by YAC755b11.
In study II, based on the results from study I, eight YAC clones (793d9,
755b11, 913g9, 957e4, 771d4, 939b12, 785e12, and 911f2) were used. These YAC
probes constitute a contig of 7.8 Mb in size spanning the region 11q23.1-q23.3
(Figure 1. on page 18). All of the YAC probes hybridized only to 11q22-q23 and none
of them showed chimerism. YAC 953a4 (CEPH-Généthon), mapped to 11p13, was
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used as the chromosome copy number control. The identities of the YAC probes were
confirmed by PCR with their corresponding markers.
In study III, YAC probe 755b11 was used.
The yeast cells containing the probes were grown in AHC medium for 4-6
days and DNA was extracted from the yeast by using a glass bead and phenol based
procedure (Hoffman & Winston, 1987).
7.4.3 Dual-color and single-color FISH
In dual color FISH, the control and test DNA were labeled with digoxigenin-dUTP
and biotin-14-dATP, respectively, by nick-translation according to the standard
procedure. In single color FISH, the DNA was labeled with biotin-14-dATP. The
probe mixture contained approximately 1 µg labeled DNA, 25 µg human Cot-1 DNA
(Gibco) and 25 µg herring sperm DNA (Sigma Chemical Co., Bornem, Belgium)
dissolved in 50% formamide and 10% dextran sulfate in 2×SSC. The probe mixture
was denatured at +75˚C for 5 minutes before the hybridization.
The nuclei preparations extracted from paraffin embedded samples were first
deparaffinized as described on page 35-36. In order to increase the hybridization
efficiency, the slides were treated in 1 M sodium thiocyanate at +70°C for 15 minutes,
followed by treatment in 0.05 N HCl at +37°C for 10 minutes and in 5 mg / ml pepsin
dissolved in 0.05 N HCl at +37°C for 20 minutes. The slides were then denatured in
70% formamide / 2 × SSC (pH 7) at +75°C for 5 minutes. The fresh tissue or blood
samples preparations were treated with 0.01 N HCl at +37°C for 5 minutes and with 5
mg / ml pepsin dissolved in 0.01 N HCl at +37°C for 7 minutes, and then denatured in
70% formamide / 2 × SSC (pH 7) at +65°C for 2 minutes. The denatured probe
mixture was hybridized onto the slides and the reaction continued for at least two
days in a moist chamber at +37°C.
After the hybridization reaction, the slides were rinsed once in 2 × SSC and
twice in 0.1 × SSC at +45°C for 5 minutes each. In dual-color FISH, the biotinylated
test DNA was detected by incubating the slides at +37°C with the avidin-TRITC
solution (1:5000, Vector laboratories, Burlingame, CA, USA), the biotinylated anti-
avidin solution (1:1000, Vector) and the avidin-TRITC solution (1:5000) for 40, 45,
and 40 minutes, respectively. Simultaneously, the digoxigenin-labeled control DNA
was visualized with the mouse-anti-digoxigenin solution (1:100, Boehringer
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Mannheim, Germany), the rabbit-anti-mouse FITC solution (1:300, Sigma, St. Louis,
MO, USA) and the goat-anti-rabbit FITC solution (1:200, Sigma) for 60, 40, and 40
minutes, respectively. In single-color FISH, the biotinylated DNA was detected by
incubation at +37°C with the avidin-FITC solution (1:200, Vector), the biotinylated
anti-avidin solution (1:1000, Vector) and the avidin-FITC solution (1:200) for 40, 45,
and 40 minutes, respectively. The preparations were counter-stained in 2 µg/ml of
DAPI for 10 minutes.
From each preparation a minimum of 200 morphologically intact and non-
overlapping nuclei were checked using a Leitz fluorescence microscope (Laborlux D,
Germany). The locus was considered deleted if the frequency of cells with only one
signal was higher than the cut-off value. The cut-off value for deletion was obtained
by experiments on normal reactive lymphoid tissue samples. The cut-off level was
defined as the mean value of the frequencies of nuclei exhibiting one signal plus three
times the standard deviation.
7.5 RNA and DNA extraction (study IV and V)
Total RNA of mononuclear cells collected from heparinized blood of CLL patients
was isolated using the TRIzol Reagent (Life Technologies Inc., Grand Island, NY,
USA) according to the manufacturer's instruction (study IV). Total RNA was isolated
from lymphoma specimens preserved at –120 ˚C using the RNeasyMini Kit from
QIAGEN (Valencia, CA, USA) according to the manufacturer’s instruction (study V).
For array analysis, the total RNA was treated with DNase according to the
manufacturer’s instruction (Clontech Laboratories Inc., Palo Alto, CA, USA). The
purity and the integrity of the RNA were examined by electrophoresis on 1% agarose
gel. Only high quality RNA was used for gene expression analysis.
DNA was extracted from deep-frozen tissue, blood or bone marrow samples
from CLL and MCL patients, using the phenol-chloroform extraction method (study
IV). In four cases of MCL, DNA was extracted from archival paraffin-embedded
material according to the protocol described elsewhere (Isola et al., 1994).
The RNA and DNA of the control samples were extracted using the same
method as the patient samples in each study.
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7.6 RT-PCR analysis (study IV)
We used RT-PCR to detect mutations in the PPP2R1B gene using total RNA from ten
CLL patient samples in study IV. 0.8 µg RNA was reverse-transcribed to cDNA in a
20 µl reaction mixture using the standard random priming method with M-MLV
reverse transcriptase (Promega, Madison, WI, USA) and RNAse inhibitor (Promega)
according to the manufacturer’s instruction. The subsequent PCR analysis was usually
performed using 3 µl cDNA, 1 × PCR buffer  (Perkin-Elmer, Branchburg, NJ, USA),
250 µM dNTPs (Finnzymes, Espoo, Finland), 0.8 µM forward and reverse primers,
and 2 units of AmpliTaqGOLD polymerase (Perkin-Elmer) in a final volume of 50 µl.
The MgCl2 concentration was 1.5 mM. Primers were designed using the primer 3
program (http://www-genome.wi.mit.edu/).
7.7 PCR-SSCP analysis (study IV)
PCR-SSCP is a method to detect mutations, polymorphisms and sequence variants,
utilizing the property that the electrophoretic mobility of single-stranded nucleic acid
depends both on the length and the sequence of the target. We used PCR-SSCP to
detect genomic mutations in the PPP2R1B gene in study IV. Primers for PCR
analysis on genomic DNA were designed using the primer 3 program (http://www-
genome.wi.mit.edu/). The reactions were carried out in a 50 µl reaction volume
containing 100 ng of genomic DNA, 1 × PCR buffer (Perkin Elmer), 250 µM dNTPs
(Finnzymes), 0.6 µM forward and reverse primers, and 2 units of AmpliTaqGOLD
polymerase (Perkin Elmer). The concentration of MgCl2 was optimized to 1-2.5 mM
in the reaction mixture for each exon and 6% DMSO was used in reactions for exon 1.
In reactions for exon 8, the concentrations of the forward and reverse primers were
0.5 µM and 1µM, respectively.
After PCR, equal volumes of the reaction mixture and the denaturing loading
buffer (95% formamide, 20 mM EDTA, 0.05% bromphenol blue and 0.05% xylene
cyanole) were mixed. The mixture was denatured for 5 minutes at +95°C and loaded
onto a 0.4 mm × 30 cm × 45 cm gel. The gel contained 0.5 × mutation detection
enhancement gel solution (FMC Bioproduct, Rockland, ME, USA) and 1 × TBE
buffer. The gels were electrophoresized at 3-6 W overnight and then stained with
silver according to the standard protocol.
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7.8 Sequencing PCR products (study IV)
In order to determine the nucleic acid sequences in mutated samples, we sequenced
PCR products showing aberrant bands in either the RT-PCR analysis or the PCR-
SSCP analysis in study IV. The PCR product was purified using a QIAquick PCR
purification kit (Qiagen) and DNA fragments were sequenced using an ABI PRISM
Dye Terminator (Perkin Elmer) according to the manufacturer’s instruction. Cycle
sequencing products were then electrophoresized on 6% Long Ranger gels (FMC
Bioproduct) and identified using an Applied Biosystems model 373A automated
DNA sequencer (Perkin Elmer). The DNA fragments were sequenced using both
forward and reverse primers.
7.9 Southern blotting analysis (study IV)
In some samples PCR-SSCP analysis was not successful in consecutive exons. In
order to see if this was due to deletions spanning more than one exon in the samples,
we performed the Southern blotting analysis. EcoR I (New England Biolabs, Beverly,
MA, USA) and TaqI (New England Biolabs) restriction enzymes were used to digest
genomic DNA (10 µg). The digested DNA was fractionated according to size in 0.8%
agarose gel (Bio-Rad, Hercules, CA, USA). After denaturation and neutralization
treatment, DNA fragments were blotted onto Hybond-C extra filters (Amersham,
Piscataway, NJ, USA). A cDNA probe containing PPP2R1B exons 1-9 was labeled
radioactively with [α32P] dCTP using standard methods and hybridized to the DNA
on the filters. After hybridization, the filters were washed at least twice in 3 × SSC
and 0.1% SDS at +65°C for 20 minutes each.
7.10 PAGE analysis (study IV)
After PCR-SSCP analysis, we found abnormal bands in exon 1 of the PPP2R1B gene
in some samples. To confirm this finding, we performed the PAGE analysis. PAGE
was performed using Ultrapure Sequagel (National Diagnostics, Atlanta, GA, USA).
The gels were silver-stained. The reactions were performed according to the standard
protocol.  
7.11 cDNA array analysis (study V)
In order to study the gene expression profiles of common and blastoid variant MCL,
we performed cDNA array analyses using the Atlas Human Hematology/Immunology
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cDNA expression array (7737-1) (Clontech Laboratories Inc). The array includes 406
human genes and nine housekeeping genes immobilized in duplicate dots on a nylon
membrane. The 406 genes included were previously shown to be involved in various
hematological and immunological disorders or in the normal functions of the human
immune system. The names of the genes and their coordinates on the filter are
available on-line (http://www.clontech.com/atlas/genelists/index.shtml).
Total RNA (3 - 4 µg) was reverse-transcribed into cDNA with primers provided
with the reaction kit by Clontech Laboratories Inc. and was labeled with 33P-dATP.
Probe purification and hybridization to the array were performed according to the
manufacturer’s instruction. After the post-hybridization washes, the array was
exposed to an imaging plate (BAS-MP 2040S; Fuji, Tokyo, Japan) at room
temperature for 3-5 days and scanned by a phosphorimager (Bio-Imaging Analyzer,
BAS-2500; Fuji). The image was analyzed and the intensity of each spot was
quantified using the Atlas Image 1.5 software (Clontech Laboratories Inc.). The
background was determined as the average intensity of the blank space between the
different panels of the array. Saturation of the hybridization signal was not observed.
All filters used were from the same batch to minimize printing variation between
batches.
7.12 Gene expression data analysis (study V)
Three statistical analysis methods were used to analyze the array data: the regression
analysis, the principal component analysis (PCA) and the naive Bayes classifier. The
first two methods focused on identifying deregulated genes and the third one provided
a model for the differential diagnosis of common MCL and its blastoid variant.
In regression analysis, Microsoft Excel 2000 software was used to generate
the xy-scatterplot of expression data from array experiments on one sample and the
control. The same software was used to determine the least-squared regression line
and the Pearson correlation coefficient of the scatterplot. The 95% confidence interval
around the regression line was determined. Spots beyond this area were identified as
abnormally expressed (Smid-Koopman et al., 2000). If a gene was found abnormally
expressed in more than 3 samples, it was considered deregulated in MCL. By
comparing the frequencies at which a gene was identified as abnormally expressed in
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common and blastoid variant MCL samples, we were able to identify genes that were
differentially deregulated in the two types of MCL.
The Principal Component Analysis (PCA) method combined the expression
data from all 18 samples and compared it to the control. Each gene was given a score.
Genes with a score around zero were considered normal and genes with big positive
or negative scores were considered deregulated. Technically, from the absolute
intensity of each gene, the background intensity was first subtracted, followed by the
subtraction of the control intensity, then the mean value of the data set of an array was
subtracted from each data point. To give equal weighting to all cases, the data in each
case was standardized to unit variance by dividing all the values by the standard
deviation. The covariance matrix is estimated from the data and the principal
components are given by eigenvectors and associated eigenvalues of the covariance
matrix. The first principal component is the eigenvector that has the largest
eigenvalue of the covariance matrix. The first principal component is interpreted as
the average expression level of each gene (Hilsenbeck et al., 1999). The gene were
scored based on their first principal component projections.
The naive Bayes classifier has been widely used in diagnostic applications
(Duda et al., 2001). In this method, we assume that the expression level of each
differentially deregulated gene in each class is distributed according to a normal
distribution. We may estimate the parameters of the normal distribution. The
parameters for each class distribution are the mean vector and the diagonal covariance
matrix. The parameters were estimated by the method of maximum likelihood by
assigning the average value and the diagonal covariance matrix of the sample to the
mean vector and the covariance matrix of the class densities, respectively. Once the
parameters of the classifier have been estimated, the model can be used for
classification. In order to assess how well the classifier would operate in a clinical
setting, where cases with unknown diagnosis are encountered, we applied the leave-
one-out cross-validation method (Golub et al., 1999). In this case, we calibrated a new
classifier based on data from 17 samples and assessed its accuracy with the 18th
sample, and repeated this effort 18 times with all possible combinations to assess the
accuracy of the classifier. The cross-validated test error is the average of all errors
made during the testing phase. To check whether the classification results are
significant, we performed a randomization experiment. The class labels of the
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observations were randomly permuted, and a new classifier was derived using the
same method as for the original data. The accuracy of the new classifier is compared
to the original classifier. This procedure was repeated 10.000 times.
7.13 Real-time PCR analysis (study V)
Real-time PCR utilizes fluorescence labels to detect PCR products. Thus, the reaction
process (in terms of PCR product amount) can be followed at real time and the
product can be quantified. In study V, we used real-time PCR to confirm the array
results. Four genes were tested, namely AF17, ADA, RGS2 and CMYC, by the real-
time PCR analysis. 820 ng purified RNA was reverse-transcribed using the 1st strand
cDNA synthesis kit for RT-PCR (AMV) (Roche Diagnostics Corp., Indianapolis, IN,
USA). The cDNA was diluted 10-fold prior to PCR amplification. Real-time PCR
was performed using the LightCycler rapid thermal cycler system (Roche Molecular
Biochemicals, Mannheim, Germany) according to the manufacturer’s instruction. The
primers were designed by TIB Molbiol (Berlin, Germany).
Reactions were performed in a 10 µl volume with primer concentrations of 0.5
µM each, Mg2+ concentration optimized between 2-5 mM, and 1 µl of cDNA. The
LightCycler-FastStart DNA Master SYBR Green I kit was used (Roche Diagnostics
GmbH, Mannheim, Germany). To confirm amplification specificity, the PCR
products from each primer pair were subjected to the melting curve analysis and
subsequently gel electrophoresis analysis.
8 RESULTS
In this thesis study, we first tried to identify the critical regions in 11q22-q23 using
FISH analysis on samples of MCL and CLL. We identified two critical regions, one
of which was the minimal common region of deletion in 11q22-q23. We then used the
probe representing this minimal common region of deletion to study the occurrence of
the deletion in 11q22-q23 in different lymphoma subtypes. In study IV, we performed
mutation analysis on one candidate gene in 11q23. Finally in study V, we investigated
the gene expression profiles of common and blastoid variant MCL using the cDNA
array analysis.
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8.1 Deletion in chromosome bands 11q22-q23 in mantle cell lymphoma
(study I)
We studied 41 MCL samples by FISH analysis in study I. We first screened 17 MCL
samples with 20 YAC probes covering the whole area of 11q22.1-q23.3. We found
deletions in this area in nine samples (53%). The deletion was usually large, spanning
several megabases, although in one sample, only the region represented by
YAC755b11 (1.6 Mb) in 11q23.1 was deleted. We then screened additional 24 MCL
samples with the probe 755b11 and found deletions in 11 samples, yielding an overall
frequency of deletion of 49% in all samples (20/41). The deletion was present in at
least 25% of the nuclei examined and in most samples it occurred in more than 60%
of the nuclei. In one case, a large biallelic deletion was detected. Two signals were
seen with a control probe in more than 78% of the cells.
The region represented by the YAC probes 785e12 and 911f2, at the distal end
of 11q22-q23, seemed to be rather critical, because the deletion ended here in most of
the informative cases (12/19, 63%). In two cases, the end point of the deletion
occurred between the region represented by probes 911f2 and 822g8. In one case, it
was between the region represented by probes 939b12 and 785e12.
The proximal end point of the deletion was not determined, because the
deletion usually extended beyond 11q22.1. In some lymphoma samples, two or three
signals were found by probes 711d4 and 939b12 while the flanking regions were
deleted.
We studied the association between the presence of a deletion in this region
and clinical parameters. No association was found between the presence of a deletion
and median age, gender, International Prognostic Index, or Ann Arbor stage of the
patients.
8.2 Discontinuous deletion in 11q23 in chronic lymphocytic leukemia (study II)
No numerical abnormality or translocation involving chromosome 11 was found in
any of the CLL cases. Standard cytogenetic analysis revealed deletions in 11q in six
samples (nos 1, 2, 9, 11, 18 and 20). Five of these samples had other chromosome
abnormalities. FISH analysis confirmed these cytogenetic findings and revealed three
more samples (nos 3, 25 and 30) with the deletion in 11q23. The overall frequency of
11q deletion was therefore 30% (9/30). In each of the samples with the deletion in
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11q23, the percentage of cells showing deletions ranged from 22% to 93% (mean,
77%). Five samples had discontinuous deletions.
The genomic region represented by the YAC probes 793d9, 755b11 and 913g9
was deleted in all the samples that had the deletion. The region represented by YAC
785e12, located about 4 Mb distal from 755b11, was deleted in all but one of the
samples (no. 2). The area in between, represented by YAC probes 957e4, 771d4 and
939b12, was deleted discontinuously in five samples (case nos 3, 9, 18, 20 and 30). In
sample nos 3, 9 and 30, the region represented by YAC 785e12 was deleted while
both of flanking regions were not.
In sample nos 3 and 9, two signals were seen at their normal positions in 11q
when probes 771d4, 939b12 and 911f2 were hybridized to the metaphase spreads of
the samples, confirming that there was no deletion of these regions in these samples.
The same was true when sample no. 24 was hybridized with probes 771d4 and
939b12. Dual-color FISH on metaphase spreads from sample nos 3, 9, 18 and 30,
with probes 755b11 and 785e12, showed that the deletions in these regions affected
the same chromosome. No signal splitting was found in sample nos 3, 9 and 30 when
dual-color FISH was performed on interphase cells with probes 939b12 and 911f2,
suggesting that there were no translocations involving these regions.
8.3 Deletion in 11q23 in different lymphoma subtypes (study III)
We studied 146 lymphoma or leukemia samples and 15 control samples by FISH
analysis in study III and found deletion of the region represented by YAC755b11 in
40 samples (25%). MCL had the highest deletion frequency with 23 out of 47 samples
(49%) having the deletion. No significant difference in frequencies were found
between common and blastoid variant MCL. Out of the 62 CLL/SLL samples studied,
13 (21%) had the deletion. The deletion is more common in the blood specimens of
CLL/SLL (9 out of 30, 30%) than the lymph node specimens of CLL/SLL (4 out of
32, 13%). Four out of the 17 (24%) DLBCL samples were found to have the deletion.
There were three cases of Richter’s syndrome among the CLL/SLL and the DLBCL
patients, and they all had the deletion. None of the nine FLs, 11 HLs or the 15
reactive or normal lymph node specimens had the deletion. The percentage of cells
showing the deletion ranged from 22% to 95% (mean, 72%).
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No significant difference was found in the deletion frequencies between men
and women (MCL, p=0.86; CLL/SLL, p=0.74; DLBCL, p=1.00). Neither was there
difference in age at diagnosis between the cases with or without the deletion in any of
the subtypes of lymphoma (MCL, p=0.89; CLL/SLL, p=0.17; DLBCL, p=0.82).
The deletion was more common in MCL than in other types of lymphoma
(MCL vs CLL/SLL: p=0.0021; MCL vs DLBCL: p=0.069). The difference in deletion
frequencies between CLL/SLL and DLBCL was not statistically significant (p=1.00).
Although the deletion frequency is higher in blood samples than in lymph
node samples of CLL/SLL (30% vs 13%), the difference is not statistically significant
(P = 0.045).
8.4 Mutation analysis of the PPP2R1B gene (study IV)
Ten CLL samples were subjected to the RT-PCR and sequencing analysis. Exon 3 of
the PPP2R1B gene was found deleted in sample no. 16.
We performed PCR-SSCP analysis on the genomic DNA of 26 additional
CLL samples and 37 MCL samples. Ninety-six percent of the PCR experiments were
successful. After the SSCP analysis, no abnormality was found in exons 2-15 in any
of the samples. One CLL sample (No. 52) showed abnormal bands in the analysis of
exon 1, which was confirmed by the PAGE analysis. The sequencing analysis showed
that this abnormality was a silent mutation CTA (Leu)- CTG (Leu) at codon 22.
To see if there were large deletions spanning several exons, we did Southern
blotting analysis on 20 MCL samples and 18 CLL samples (two of the CLL samples
studied by the RT-PCR analysis, nos 16 and 41, were also included in the RT-PCR
analysis). Experiments on DNA digested by TaqI yielded informative results from 8
MCL samples and 17 CLL samples. Experiments on DNA digested by EcoRI yielded
informative results from seven MCL samples but failed in all CLL cases because of
the poor quality of the DNA. A structural rearrangement of the PPP2R1B gene was
found in one MCL sample (no. 33). Details of this rearrangement could not be studied
because RNA was not available.
Altogether, therefore, we found two abnormalities in the PPP2R1B gene, a
deletion of exon 3 in one CLL sample (no. 16) and a structural rearrangement in one
MCL sample (no. 33).
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8.5 The gene expression profiles of MCL and its blastoid variant (study V)
The regression analysis identified 46 deregulated genes. Thirty-four of them were
found to be deregulated in both common and blastoid variant MCL at frequencies
ranging from 22% to 100%. The remaining 12 genes were found to be differentially
deregulated in common and blastoid variant MCL. In PCA, we chose 20 genes with
the highest scores and 20 genes with the lowest scores as the deregulated genes for
MCL. Genes identified by both the regression analysis and PCA were considered
deregulated in both common and blastoid variant MCL. There were 18 such genes
(Table 5).
Table 5. Genes deregulated in both common and blastoid variant MCL
Gene name Chromosome location Status Suggested role in MCL
SCYA21 9p13 Up Normal body function
GPR13 3p21.3 Up Not known
BCL1 11q13 Up Oncogene
AF17 17q21 Up Not known
MIG 4q21 Up Normal body function
CD5 11q13 Up Not known
ANX2 15q21-q22 Up Tumor metastasis promoter
CD44H 11p13 Up Tumor metastasis promoter
TP12/CD6 11q13 Up Not known
TCF7 5q31.1 Up Not known
GRN 17q21.32 Up Oncogene
GZMK 5q11-q12 Up Normal body function
EBI2 13 Down Not known
ADA 20q12-q13.11 Down Not known
CALLA/CD10 3q25.1-q25.2 Down Oncogene
CD66D 19q13.2 Down Tumor suppressor
RGS1 1q31 Down Tumor metastasis promoter
RGS2 1q31 Down Tumor metastasis promoter
The expression data of the 12 genes differentially deregulated for common and
blastoid variant MCL were used to calibrate the naive Bayes classifier. The leave-one-
48
out cross-validation tests showed correct classification in 14 out of the 18 cases.
Therefore, the cross-validated test error for the classifier was 0.222. The
randomization experiments yielded a significance level of 0.028.
To improve the classification, we used subsets of the 12 genes to calibrate the
classifier. This had not only the potential to provide a more accurate classifier, but
was also a way to choose and confirm the differentially deregulated genes. We tested
gene sets consisting of one to eleven genes with different gene composites. It turned
out that the best classifier is a gene set consisting of eight genes. The mean
classification error was 0.111. Randomization results yielded a significance level of
0.018. Therefore, we conclude that these eight genes are significant in separating the
blastoid variant from common MCL and they are differentially deregulated in
common and blastoid variant MCL (Table 6).
Table 6. Genes differentially deregulated in common and blastoid variant MCL
Gene
Name
Chromosome
location
Status Deregulated in
common MCL
Deregulated in
MCL blastoid
variant
Suggested role in
MCL
CMYC 8q24.12-
q24.13
Up 0 44% Oncogene
BCL2 18q21.33 Up 33% 56% Oncogene
TOP1 20q12-q13.1 Up 67% 11% Not known
CD45 1q31-q32 Up 56% 0 Tumor suppressor
CD70 19p13 Up 22% 56% Oncogene
NFATC 18q23 Up 56% 11% Functions through
downstream targets.
PIM1 6p21.2 Up 0 56% Oncogene
CD23 19p13.3 Down 33% 67% Not known
To confirm the cDNA array results, we did real-time PCR analysis on four
genes, AF-17, ADA, RGS2 and CMYC. The results were in accordance with the array
analysis results.   
49
9 DISCUSSION
9.1 Discussion of the techniques applied
Control samples
We used lymph node biopsy specimens from two healthy individuals as controls in
study I, and peripheral blood specimens from two healthy individuals as controls in
study II. The control samples were tested by 20 YAC probes in study I and 8 in study
II. In each experiment, a total of 200 nuclei were analyzed. The frequency of normal
nuclei with one-signal in each experiment was determined. The average frequency
and the standard deviation were calculated, and the cut-off level was determined as
the average frequency plus three times the standard deviation. If the frequency of
nuclei with one-signal in a FISH experiment on one patient sample is higher than the
cut-off level, we consider the region represented by the probe is deleted in the sample.
We studied 15 normal or reactive lymph node specimens with YAC755b11 in
study III. In addition to determine the cut-off level, these samples were used to
determine the occurrence of the deletion in 11q23 in normal lymph node tissues.
In study IV, we used DNA and RNA extracted from the peripheral blood of
two healthy individuals as controls. To determine whether a point mutation is a
polymorphism, one usually needs a larger series of normal samples. In this study, no
point mutation was found. Therefore, we think two control samples are sufficient.
Choosing the proper control is perhaps the most difficult part of the array
analysis. In many cancer types, the normal cell counterparts are still unknown or
controversial. In addition, to get enough amount of the normal cell counterpart from
healthy individuals is often difficult. In study V, we used the B-cells purified with
CD19-coupled microbeads from adenoid palatine tonsil samples from six healthy
children as the control. Whether this control is the most suitable normal cell
counterpart of MCL malignant cells can be argued. Theoretically, the normal cell
counterpart of MCL malignant cells is the CD5+ B-cell from the mantle zone of
lymph nodes. The B-cells extracted from tonsils are normally CD5-. The CD19 is a
pan-B-cell marker, which is expressed not only on mantle zone B-cells, but also on
germinal center and marginal zone B-cells. In addition, the patients were mostly over
60 years old, while the control samples were extract from children. However, to get
enough CD5+ cells from the mantle zone of lymph nodes from healthy old men is
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practically impossible. The alternative could be CD5+ B-cells enriched from the
blood. But a recent study by Rosenwald et al. (2001) (Rosenwald et al., 2001) has
shown that there is no similarity in gene expression profiles between CD5+ B-cells
enriched from blood and CLL malignant cells. CLL is another disease whose normal
cell counterpart is proposed to be the CD5+ B-cell. Rosenwald et al. (2001) suggested
that the gene expression profile in CLL might be a manifestation of oncogenic
properties and therefore might not be a feature of any normal B-cell population.
Although the same kind of study has not been conducted in MCL, we think that
similar conclusions can be drawn for MCL as well. Based on these facts, we think our
choice of the control is suitable for this study. We were, however, careful when
interpreting the deregulated genes. We used two statistical analysis methods to
confirm the genes identified as deregulated: regression analysis and PCA in
identifying genes deregulated in both common and blastoid variant MCL; regression
analysis and naive Bayes classifier in identifying genes differentially deregulated in
common and blastoid variant MCL. The stringent selection criteria guaranteed that
the genes chosen by both methods were indeed deregulated. However, we should be
aware that this selection process might have eliminated genes with low degree of
abnormality but of biological importance. Therefore, genes chosen by one statistical
analysis method as deregulated but not by the other also deserve attention.
Interphase FISH
Either dual-color or single-color interphase FISH was applied in studies I, II and III.
One of the biggest advantages of interphase FISH is that we can utilize the paraffin-
embedded archival material. Since the paraffin-embedded material is much more
abundant than the fresh or deep-frozen one, interphase FISH enables us to conduct the
research on larger series of patient material. The disadvantage of interphase FISH is
that it is rather labor-intensive, especially when multiple probes are tested on large
sample series. Over 700 FISH experiments were performed in this thesis study, which
has been both time and money consuming. Therefore, it is necessary to combine
interphase FISH with other high-throughput methods, such as the tumor array
technology, in order to increase the efficiency.
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Mutation analysis
We used PCR-SSCP as the main method for detecting mutations in the PPP2R1B
gene. PCR-SSCP is a popular electrophoretic method for the detection of mutations. It
is technically simple, with high capacity and relatively high sensitivity. There are a
number of factors affecting the sensitivity of PCR-SSCP: choice of matrix,
electrophoretic conditions, presence of additives, and the fragment size and GC
content of the sample. It has been shown that the sensitivity of PCR-SSCP is between
70% and 95% depending strongly on the factors described above (Moore et al., 2000).
Except the sample’s fragment size and GC content, we optimized all the other factors
for each exon before the experiments. Mutation of one nucleotide was detected in our
study, proving the sensitivity of our experiments. However, we can not exclude the
possibility that some mutations were not detected because PCR-SSCP experiment
conditions were not optimal for some exon sequences.
Perhaps the most sensitive method for mutation detection is the sequencing of
the cDNA transcribed from RNA. However, the availability of RNA has often been
the restricting factor. Direct sequencing of the genomic DNA (including exons and
exon-intron boundaries) is also a very sensitive method. However, it is very costly to
conduct such analysis on large series of samples, especially when the gene under
investigation has many exons. In addition, direct sequencing of genomic DNA cannot
detect large deletions spanning more than one exon. Thus, assisting methods, such as
Southern blotting analysis, have to be used to make the investigation complete.
Statistical methods used in the array analysis
In most of the array studies, the ratio of a gene’s expression level in tumor samples to
its expression level in the control sample plays an important role (Eisen et al., 1998).
The glass-based array system is very convenient and accurate, because both the tumor
RNA and the control RNA are simultaneously hybridized onto the array, leading to
minimal inter-experimental variations. The inter-experimental variations are
considerably higher using the filter-based array system, because the tumor and control
RNA are hybridized to the array in two independent experiments. Therefore we
needed analysis methods that could best solve the normalization problem. The
regression analysis treats the expression levels of all genes in an array experiment as a
population and compares it with another population. The coefficients a and b in the
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regression function y = ax + b should, in principle, explain the major inter-
experimental variants, namely the overall intensity variation caused by the different
amounts of RNA used, and the background variation caused by different exposure
time. In PSA, we subtracted the average value of all gene expression data on an array
from the expression data of each gene, then divided this figure with the variance. This
is also a powerful way to normalize the expression data.
The regression analysis is, however, rather laborious, especially if there are a
large number of samples. Another disadvantage was the use of frequencies, which are
sensitive to the choice of thresholds. The PCA is less labor intensive. It is also more
powerful in treating the sample set as a group.
There are enormous interests in the tumor class prediction and classification
field. Most impressively, many creative statistical analysis strategies are being
applied. In our study, we used the naive Bayes classifier. This method and its variants
have been applied to the classification of cancer before (Golub et al., 1999; Dudoit et
al., 2000). We were able to verify the accuracy of this classifier by the cross
validation tests. Although it is statistically sufficient, the true value of this classifier
will only be shown when new MCL cases are correctly diagnosed. It is conceivable
that with more samples and an array containing more genes, we will be able to gain
much more information about the disease and generate a more accurate classifier.
9.2 The minimal common region of deletion in 11q22-q23 (study I, II)
By utilizing the YAC-contig, we wanted to narrow down the critical regions in
11q22-q23. In study I, the minimal common region of deletion in 11q22-23 was found
to be the region represented by YAC755b11. In study II, the same genomic region
was involved in all cases with the deletion. In one case, the region represented by
YAC755b11 was deleted more frequently (63%) than the flanking regions (42% and
31%, respectively). This suggested that part of the cell population had the deletion
only in the region represented by YAC755b11. Similar results have been obtained by
others (Stilgenbauer et al., 1996). The YAC755b11 probe was also used to screen 214
CLL cases. Deletions were found in the cases that had an inferior prognosis (Döhner
et al., 1997). These data suggested that 11q23.1 might contain a tumor suppressor
gene that could be important in the pathogenesis of both MCL and CLL. Our results
support the conclusion that this tumor suppressor gene is located in the region
represented by YAC755b11. However, the study by Stilgenbauer et al. (1999) on 81
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MCL cases showed that the minimal common region of deletion in 11q23 was the one
represented by YAC801e11, a region more proximal than the region represented by
YAC755b11 (Stilgenbauer et al., 1999). This is the region where the ATM gene is
located. Subsequent analysis of the same samples confirmed the inactivation of the
ATM gene, leading to the conclusion that the ATM gene was the proposed tumor
suppressor gene in 11q23 (Schaffner et al., 2000). Nevertheless, the significance of
the region represented by YAC755b11 should not be neglected. It is highly possible
that there is one yet unknown tumor suppressor gene in this region, as was evidenced
by our results and the translocations found by Stilgenbauer et al. (1996) in this region.
Additional evidences came from the mutation analysis of the ATM gene in CLL,
where mutation was not found in a fraction of CLL cases that had the monoallelic
11q23 deletion (Schaffner et al., 1999).
9.3 The second critical region in 11q22-q23 (study I, II)
In addition to the region represented by YAC 755b11, we found another critical
region in 11q23. In study I, the distal end point of the 11q22-q23 deletion was found
to be between the regions represented by YACs 785e12 and 911f2 in the majority of
samples studied (63%). Interestingly, the two regions were found deleted in cases
where the deletion was discontinuous. In study II, the region represented by
YAC785e12 was deleted in eight out of the 30 samples studied (27%), and in three
samples this region was deleted while the flanking regions remained intact. Our
results suggested that the region represented by YAC785e12 and its vicinity were the
second critical region in 11q22-q23. The region might contain another yet unknown
tumor suppressor gene.
YACs 785e12 and 911f2 are mapped to 11q23.3, the region that often contains
structural aberrations and rearrangements in hematological malignancies (Heim &
Mitelman, 1995). This region also contains inherited and constitutionally fragile sites,
which makes it susceptible to chromosome breakage and rearrangements (Sutherland
et al., 1983; Yunis & Soreng, 1984). In addition to hematological diseases, loss of
heterozygosity of the marker APOC-3 that is located in the region represented by
785e12 has been found frequently in breast carcinomas (Laake et al., 1997) and
cervical carcinomas (Hampton et al., 1994b) (frequencies of 45% and 43%,
respectively), suggesting the existence of a tumor suppressor gene in this region.
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In our study, the deletion in 11q23 in one sample did not involve the region
represented by YAC 785e12. Similarly, Stilgenbauer et al. (1996) have reported that
seven out of 18 CLL samples in their study did not have the deletion of this region.
One explanation might be that a part of this region could have been deleted but was
beyond the resolution limit of FISH. In study II, dual-color FISH on metaphase
spreads with YACs 785e12 and 755b11 showed that the deletion of the two regions
occurred in the same chromosome, implying that the deletion of the region
represented by YAC785e12 might be a secondary event associated with the deletion
of the region represented by YAC755b11. The deletion of the region represented by
YAC785e12 might therefore be a late event in the disease progression and might not
be present in cases at early stages of the disease.
A tumor suppressor gene, TSLC1, was identified recently in non-small-cell-lung
cancer. This gene is located in the central 100-kb fragment of the region represented
by YAC939b12, which is very close to the region represented by YAC785e12
(Murakami et al., 1998; Kuramochi et al., 2001). It will be interesting to see if this
gene has a role in the pathogenesis of MCL and CLL.
9.4 The 11q23 deletion in different lymphoma subtypes (study I, II, III)
Our results have shown that the deletion in 11q23 is not uniformly present in NHL.
We studied 47 MCL samples in studies I and III, and the deletion in 11q23 was found
in 49% of them. Similar results were obtained by Stilgenbauer et al. (1999), who
found that 37 out of 81 MCL samples (46%) had the deletion in 11q23. Nine out of 30
blood samples of CLL/SLL (30%) were found to have the deletion in 11q23, while
only 13% (4 out of 32 samples) of the lymph node biopsies of CLL/SLL had the
deletion (study II & III). The combined frequency in CLL/SLL is therefore 21% and it
is similar to the 20% deletion frequency obtained by others (Döhner et al., 1997). The
deletion was found in 24% (4 out of 17) of DLBCL samples, and was absent in FL
and HL. For HL, however, we ought to consider that the analysis was not conducted
exclusively on the Reed-Stenberg cells that are the malignant cell population in HL
(Teerenhovi et al., 1988). The occurrence of the deletion in 11q23 in DLBCL, FL and
HL has not been reported before.
The deletion in 11q23 is significantly more frequent in MCL than in any other
lymphoma subtypes. We think the deletion in 11q23 could be used as a diagnostic
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marker of MCL in addition to the cyclin D1 overexpression. The prognostic value of
this abnormality has been shown in CLL (Döhner et al., 1997). Therefore, the 11q23
status is routinely examined using the YAC755b11 probe in the Chromosome and
Molecular Cytogenetic Laboratory at the Helsinki University Central Hospital.
About 3% of the CLL/SLL cases progress to DLBCL, which is referred to as
the Richter's syndrome (Jaffe et al., 2001). We had three Richter's syndrome cases in
our study. One was diagnosed as CLL at the time of the study; clinical follow-up
showed that this patient later developed DLBCL. The other two were diagnosed as
DLBCL at the time of the study and their records showed that they had previously
been CLL patients. Interestingly, all of them had the deletion in 11q23. Although the
sample number was small, the current result suggested that the deletion was
associated with the development of the Richter’s syndrome. CLL patients whose
tumor cells have this lesion might be more prone to develop Richter’s syndrome and
have a poor prognosis. The genes involved in the transformation might reside in this
particular region.
CLL and SLL are considered one disease entity in the WHO classification.
CLL affects primarily the bone marrow and peripheral blood, and SLL lymph nodes.
In our study, we have found that the frequencies of the deletion in 11q23 tend to be
different in the blood and lymph node specimens of CLL/SLL, although the
difference is not statistically significant. Because of difficulty obtaining the clinical
data, we did not know the lymph node involvement status of the patients whose blood
samples were tested. Out of the 32 patient whose lymph node samples were tested, 25
patients had the bone marrow infiltration. Although pair-wise comparison is not
possible, our results do suggest that the malignant cells with 11q23 deletion may have
impaired homing ability to the lymph node and therefore may be more likely to be in
the blood circulations. Our hypothesis is supported by a recent study, which
demonstrated that functionally relevant adhesion molecules and cell signaling
receptors on CLL cells are differentially expressed according to the 11q22.3-q23.1
deletion status (Sembries et al., 1999). Sembries et al. (1999) suggested that the 11q
deletion might have impaired several cellular pathways in CLL cells, changing the
migratory properties of these cells within lymphoid organs and in peripheral blood.
Studies have also shown that typical CLL (Karhu et al., 1997) and typical SLL (Autio
et al., 1998) have rather different CGH profiles. All these results urged us to question
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whether CLL and SLL are different forms of one disease or if they are actually two
distinct disease entities. This matter deserves further investigations.
We also need to bear in mind that CLL itself is a heterogeneous disease, which
can be divided into two subgroups based on the Ig V gene mutation and the CD38
expression status. Patients with unmutated Ig V gene and higher percentage of CD38+
cells have poorer prognosis (Damle et al., 1999; Hamblin et al., 1999). On the other
hand, 11q23 deletion has been found to define a subset of CLL with poor prognosis
(Döhner et al., 1997). It will be interesting to see if the patients with unmutated Ig V
gene and higher percentages of Cd38+ cells also have the 11q23 deletion. Or perhaps
11q23 deletion is an independent marker that helps to divide CLL into even more
subtypes.
9.5 The role of the PPP2R1B gene in MCL and CLL (study IV)
Since it was cloned in 1998, the PPP2R1B gene has been found to be mutated in
human lung and colon cancer (Wang et al., 1998), but not in hereditary
paraganglioma (Baysal et al., 1998), ovarian carcinoma (Campbell & Manolitsas,
1999; Wu et al., 1999) or parathyroid hyperplasia and adenoma (Hemmer et al.,
2002). In study IV, we found the deletion of exon 3 of the PPP2R1B gene in one CLL
sample and the structural rearrangement of this gene in one MCL sample. In both
cases, FISH analysis had already revealed deletions in 11q23, which could be
considered in accordance with the two-hit theory of tumor suppressor genes.
There were, indeed, some imperfections in our analyses. First, the methylation
status of the promoter region was not studied. Second, due to the limited information
on the intron sequencies available from the Genebank, none of the PCR primers
designed for SSCP analysis allowed the investigation of splice-sites. Third, the
Southern-blotting analysis was not complete due to the lack of high quality DNA
material. So we cannot exclude the possibility that abnormalities in the PPP2R1B
gene are in fact more common than is revealed by our study.
However, the mutation frequencies of the PPP2R1B gene were too low (2.7%
in CLL cases and 2.6% in MCL cases) to explain the frequent deletion in 11q23 in
CLL and MCL found by the FISH analyses (30% in CLL cases and 49% in MCL
cases). In particular, the RT-PCR analysis carried out on 10 CLL samples revealed
only one mutation, while 9 of the 10 samples had the deletion in 11q23. Therefore, we
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assume that the role of the PPP2R1B gene in the pathogenesis of CLL and MCL is
probably minor. There might be another gene or genes in the 11q23 region that play
more important roles. The ATM gene has been shown to have a pathogenic role in
MCL (Stilgenbauer et al., 1999; Schaffner et al., 2000) and CLL (Schaffner et al.,
1999). Recently, a retinoid-induced class II tumor suppressor / growth regulatory gene
was found to be involved in CLL and located in 11q23 (DiSepio et al., 1998). Its
exact location and its role in other types of cancer deserve further investigation. In
addition, as was discussed in section 9.2, there might be a yet unknown tumor
suppressor gene in the region represented by YAC755b11.
9.6 Marker genes identified by array analysis in MCL (study V)
In study V, we identified eight genes that were differentially deregulated in common
and blastoid variant MCL using the regression analysis and the naive Bayes classifier.
The most important finding is the possible involvement of the gp130 mediated
STAT3 signaling pathway in the MCL blastoid variant transformation. Three genes in
the pathway, CMYC, PIM1 and BCL2 were all up-regulated in the blastoid variant,
but not in common MCL. The product of CMYC is a major regulator of cell growth
and the deregulation of CMYC plays a central role in the pathogenesis of lymphoid
malignancies as well as other types of cancer [reviewed by (Dang et al., 1999)]. The
regulation of CMYC is coordinated via multiple signaling pathways and one of them
is the gp130-mediated STAT3 signaling pathway (Kiuchi et al., 1999). PIM1 is
frequently up-regulated in human hematopoietic cell lines as well as in tumor cells
from leukemia patients (Amason et al., 1989). It is also a target of the gp130-
mediated STAT3 signal and cooperates with CMYC to promote cell proliferation and
to prevent apoptosis. BCL2 is the downstream target of both CMYC  and PIM1
(Shirogane et al., 1999). The simultaneous up-regulation of the CMYC, PIM1 and
BCL2 gene in our study demonstrates the close relationship between them, and
suggests that the gp130-mediated STAT3 signaling pathway might be involved in the
blastoid variant transformation of MCL.
Abnormalities in CD45  and CD70  have been found in other types of
lymphoma. Reduced levels of CD45 expression has been found in CLL patients with
poorer prognosis (Sembries et al., 1999). Expression of CD70 was found in CLL, FL,
DLBCL and MCL, although CD70 was infrequently expressed in normal human B
cells in vivo (Lens et al., 1999).
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Although we are not sure of the mechanism behind the frequent up-regulation
of TOP1 in common MCL, we may be able to utilize this piece of information in
clinical trials. It will be interesting to test whether topoisomerase I inhibitors will be
effective in the treatment of common MCL.
Marker genes of both common and blastoid variant MCL were identified using
the regression analysis and PCA. All but two samples showed up-regulation of BCL1,
which is in accordance with the immunohistochemistry study. The role of cyclin D1
in MCL is well established and will not be discussed further here.
The annexin II (encoded by ANX2) heterotetramer is known to interact with a
number of tumor related proteins, e.g. tissue-type plasminogen activator (Cesarman et
al., 1994), cystein protease cathepsin B (Mai et al., 2000a), collagen-I and tenascin-C
(Chung et al., 1996). The interaction and collaboration between them may enhance
tumor cell detachment, invasion and motility (Mai et al., 2000b). The cell surface
molecule CD44 has been implicated in tumor metastasis (Sy et al., 1997). It has also
been shown that, in mammary epithelial cells, vast majority of CD44 interacts with
annexin II in lipid rafts (Oliferenko et al., 1999). Our results further demonstrated the
close relationship between annexin II and CD44, and their possible roles as promoters
of tumor metastasis.
Regulators of G protein signaling (RGS) inhibit the downstream signaling of
the G protein (Kehrl, 1998). They are shown to inhibit the migration and adhesion of
lymphoid cells (Bowman et al., 1998; Moratz et al., 2000; Reif & Cyster, 2000). Two
members of the RGS family, RGS1 and RGS2, were found to be down-regulated in
our study, suggesting a role in preventing tumor cell invasion and metastasis.
The carcinoembryonic antigen CGM1 precursor (CD66d) belongs to the CD66
family, whose members appear to have roles in various biological processes including
tumorigenesis (Thompson et al., 1991; Obrink, 1997). One of the family members,
CD66a, was shown to act as a tumor suppressor in several cancer models (Skubitz et
al., 2000). CD66d was found to be down-regulated in our study and it might also have
tumor suppressing functions.
We should be careful in interpreting the roles of three genes: T cell surface
glycoprotein CD5 precursor gene (CD5), T cell differentiation antigen CD6 precursor
gene (TP12/CD6) and T cell specific transcription factor 1 gene (TCF7). We used
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purified B cells as the reference, whereas the samples were unpurified lymphoma
specimens. The proportion of reactive T cells in mantle cell lymphoma samples may
range from 5% to 20%. It is possible that the up-regulation of these three gene was
due to the T-cell contamination.
In addition to identify marker genes in common and blastoid variant MCL, the
purpose of study V was to look for candidate genes for the proposed tumor suppressor
gene in 11q23. No candidate gene was found, partly due to the relatively small
number of genes (406) included in the array. However, we should consider this study
as a pilot study, preparing us for a larger scale array study in the future.
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10 CONCLUDING REMARKS AND PERSPECTIVES
More and more evidences coming from studies by both us and others have shown that
the 11q23 region harbors more than one tumor suppressor gene. These genes play
important roles in the pathogenesis and progression of a number of different types of
cancer, including MCL and CLL. To identify and characterize them will improve our
knowledge of these diseases as well as the general knowledge of cancer biology. It is
also the starting point of inventing new pharmaceuticals and diagnostic tools. Since
we showed that the PPP2R1B gene is unlikely to be the tumor suppressor gene we are
looking for, attention should be turned to other genes in the area. Besides ATM and
TSLC1, other, as yet unknown, tumor suppressor genes could be found in the critical
regions we identified. We could utilize the positional cloning strategy to try to
identify them: constructing cosmid contigs over the critical regions; narrowing down
the critical regions by FISH using cosmid probes; constructing a CpG island map of
the critical regions; sequencing; and so on. On the other hand, the advancement of the
array technology might offer better solutions to this problem. We could construct a
chromosome or site-specific CGH-matrix array and examine the patient genomic
DNA with it. We could also construct a chromosome or site-specific cDNA array and
directly study the abnormality in gene expression in the patient material.
The deletion in 11q23 is now widely accepted as a chromosomal abnormality
that has diagnostic and prognostic value. It is also evident that CLL patients with this
abnormality represent a distinct disease subgroup, with a unique disease progression
path and genetic profile. Whether this is true for MCL patients is still unknown and
deserves further study. The role of the 11q23 deletion in the development of the
Richter’s syndrome and its molecular background also deserves more investigation. If
a correlation could be established between the 11q23 deletion and the development of
the Richter’s syndrome, the deletion will be an important prognostic factor. The
difference in the frequencies of the 11q23 deletion in lymph node specimens and the
peripheral blood specimens in CLL/SLL is also an interesting subject. We ought to
look more closely at the genetic profiles of both CLL and SLL. The cDNA array
analysis has been used to identify separate disease groups, previously considered as
one disease entity (Alizadeh et al., 2000). With careful planning and sample selection,
we could also get more insights into the nature of these two diseases by utilizing the
array technology.
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Not only enormous quantities of biological data, but also new technologies, are
emerging with high speed in the fields of cytogenetics, molecular genetics and cell
biology. We have gained valuable biological information from our successful
utilization of various techniques throughout the studies in this thesis, as well as
experience in using the techniques. We hope that this knowledge and experience will
be beneficial to our future investigations.
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